WO2024020199A1 - Native microfluidic ce-ms analysis of antibody charge heterogeneity - Google Patents
Native microfluidic ce-ms analysis of antibody charge heterogeneity Download PDFInfo
- Publication number
- WO2024020199A1 WO2024020199A1 PCT/US2023/028357 US2023028357W WO2024020199A1 WO 2024020199 A1 WO2024020199 A1 WO 2024020199A1 US 2023028357 W US2023028357 W US 2023028357W WO 2024020199 A1 WO2024020199 A1 WO 2024020199A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- sample
- charge
- interest
- nce
- Prior art date
Links
- 238000004458 analytical method Methods 0.000 title description 48
- 238000000034 method Methods 0.000 claims abstract description 178
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 239000006227 byproduct Substances 0.000 claims abstract description 10
- 238000000926 separation method Methods 0.000 claims description 60
- 238000004949 mass spectrometry Methods 0.000 claims description 41
- 238000005251 capillar electrophoresis Methods 0.000 claims description 28
- 239000011159 matrix material Substances 0.000 claims description 26
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 238000007873 sieving Methods 0.000 claims description 6
- 230000004481 post-translational protein modification Effects 0.000 abstract description 57
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 abstract description 7
- 239000000523 sample Substances 0.000 description 103
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 52
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 47
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 239000012634 fragment Substances 0.000 description 40
- 238000001962 electrophoresis Methods 0.000 description 31
- 239000012535 impurity Substances 0.000 description 25
- 230000001225 therapeutic effect Effects 0.000 description 24
- 230000002378 acidificating effect Effects 0.000 description 23
- 238000012506 imaged capillary isoelectric focusing Methods 0.000 description 23
- 230000035945 sensitivity Effects 0.000 description 22
- 241000894007 species Species 0.000 description 22
- 238000001514 detection method Methods 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 108091005804 Peptidases Proteins 0.000 description 16
- 239000004365 Protease Substances 0.000 description 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 238000012512 characterization method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 229940049595 antibody-drug conjugate Drugs 0.000 description 11
- 238000000132 electrospray ionisation Methods 0.000 description 11
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 235000018977 lysine Nutrition 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 239000000611 antibody drug conjugate Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000011154 charge variant analysis Methods 0.000 description 9
- 230000006240 deamidation Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000036252 glycation Effects 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000012799 strong cation exchange Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000012510 peptide mapping method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 7
- 230000004989 O-glycosylation Effects 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229940043131 pyroglutamate Drugs 0.000 description 7
- 238000004885 tandem mass spectrometry Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 229940027941 immunoglobulin g Drugs 0.000 description 6
- 238000012531 mass spectrometric analysis of intact mass Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 description 3
- 101100075831 Caenorhabditis elegans mab-7 gene Proteins 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000005040 ion trap Methods 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229940126587 biotherapeutics Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012494 forced degradation Methods 0.000 description 2
- 238000012495 forced degradation study Methods 0.000 description 2
- 239000005350 fused silica glass Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 150000002669 lysines Chemical group 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000004780 2D liquid chromatography Methods 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010073361 BioXtra Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000011190 asparagine deamidation Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 102220349284 c.287A>T Human genes 0.000 description 1
- 238000005515 capillary zone electrophoresis Methods 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000035418 detection of UV Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002090 nanochannel Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220142694 rs192332456 Human genes 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000002150 sonic spray mass spectrometry Methods 0.000 description 1
- 238000012420 spiking experiment Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012437 strong cation exchange chromatography Methods 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
Definitions
- the present invention pertains to biopharmaceuticals, and relates to the use of capillary electrophoresis and mass spectral analysis to characterize size and charge variants of therapeutic antibodies.
- Therapeutic antibodies are a significant class of biotherapeutic products, and they have achieved outstanding success in treating many life-threatening and chronic diseases.
- therapeutic antibodies such as monoclonal antibodies (mAbs)
- mAbs monoclonal antibodies
- PTMs post-translational modifications
- Variants produced via PTMs can occur throughout the lifespan of a mAb during production, purification, storage, and postadministration.
- PQAs product quality attributes
- Each individual monoclonal antibody may therefore present a unique profile, a characteristic which needs to be taken into consideration during the evaluation of these products both during development and manufacturing of final product.
- a Food and Drug Administration guidance for industry recommends that sponsors should evaluate susceptibilities of therapeutic proteins to modifications within the in vivo milieu (see, Guidance for Industry, Immunogenicity Assessment for Therapeutic Protein Products. 2014).
- a method has been developed for analysis of protein variants, for example size and charge variants of a therapeutic antibody.
- the method comprises the use of native microfluidic capillary electrophoresis connected in line with mass spectrometry to separate, identify and/or quantify polypeptides in a sample.
- the method may be used, for example, to characterize post- translational modifications (PTMs) of an antibody, to detect monospecific mAb impurities (referred as either HC/HC or HC*/HC*) in a bispecific antibody (bsAb) sample, and to characterize alternative antibody formats such as “N-l,” which is a one arm antibody, and “N+l” antibodies, where an additional Fab arm was connected to the heavy chain.
- PTMs post- translational modifications
- bsAb bispecific antibody
- the present invention provides a method for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample, in which the method includes: contacting a sample comprising one or more antibodies of interest with a protease to digest the sample into antibody fragments; separating antibody fragments by molecular weight and/or charge in one or more capillaries using capillary electrophoresis; eluting separated antibody fragments from the one or more capillaries; and determining the mass of the eluted antibody fragments by mass spec analysis, thereby detecting and/or discriminating between post-translational modification variants of the antibody of interest.
- the post-translational modification comprises one or more of deamidation, oxidation, glycation, disulfide formation, N-terminal pyroglutamate formation, C-terminal lysine removal, high mannose glycosylation, and O-glycosylation.
- the protease comprises IdeS.
- the antibody fragments comprise one or more of an F(ab’)2 or Fc antibody subunit.
- the antibody of interest is a mAb.
- the antibody fragments are separated by charge and the method is a method of detecting and/or discriminating between charge variants of the antibody of interest.
- the antibody fragments are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of the antibody of interest.
- the method further includes determining a relative or absolute amount of the post-translational modification variants of an antibody of interest in a sample.
- the antibody of interest comprises a bispecific antibody.
- the sample includes an internal standard.
- the one or more capillaries comprise a separation matrix.
- the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
- eluting separated antibody fragments from the one or more capillaries further comprises separating the antibody fragments into one or more fractions.
- the method further includes identifying the antibody fragments. [0021] In some embodiments, the method further includes identifying the post-translational modification present on the antibody fragments.
- the monoclonal antibody of interest is of isotype IgGl, IgG2, IgG3, IgG4, or mixed isotype.
- the method further includes post-translational modification profiling of the antibody of interest.
- the method further includes post-translational modification mapping of post-translational modification hotspots by reduced peptide mapping LC-MS/MS analysis.
- the sample comprises a mixture of antibodies of interest.
- the monoclonal antibody of interest is an antibody drug conjugate.
- the method comprises (a) contacting a sample comprising one or more antibodies of interest with a protease to digest the sample into antibody fragments; (b) separating antibody fragments by molecular weight and/or charge in one or more capillaries using capillary electrophoresis; (c) eluting separated antibody fragments from the one or more capillaries; and (d) determining the mass of the eluted antibody fragments by mass spectrometry analysis, thereby detecting and/or discriminating between post-translational modification variants of the antibody of interest, wherein said one or more antibodies of interest are maintained in native conditions, and wherein said capillary electrophoresis is in an integrated microfluidic platform.
- the post-translational modification comprises one or more of deamidation, oxidation, glycation, disulfide formation, N-terminal pyroglutamate formation, C- terminal lysine removal, high mannose glycosylation, and O-glycosylation.
- the protease comprises IdeS.
- the antibody fragments comprise one or more of an F(ab’)2 or Fc antibody subunit.
- the antibody of interest is a monoclonal antibody.
- the antibody fragments are separated by charge and the method is a method of detecting and/or discriminating between charge variants of the antibody of interest.
- the antibody fragments are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of the antibody of interest.
- the method further comprises determining a relative or absolute amount of the post-translational modification variants of an antibody of interest in a sample.
- the antibody of interest comprises a bispecific antibody.
- the sample includes an internal standard.
- the one or more capillaries comprise a separation matrix.
- said separating comprises a sieving matrix configured to separate proteins by molecular weight.
- eluting separated antibody fragments from said one or more capillaries further comprises separating the antibody fragments into one or more fractions.
- the method further comprises identifying the antibody fragments.
- the method further comprises identifying the post-translational modification present on the antibody fragments.
- the antibody of interest is of isotype IgGl, IgG2, IgG3, IgG4, or mixed isotype.
- the method further comprises post-translational modification profiling of the antibody of interest.
- the method further comprises post-translational modification mapping of post-translational modification hotspots by reduced peptide mapping LC-MS/MS analysis.
- the sample comprises a mixture of antibodies of interest.
- the antibody of interest is an antibody drug conjugate.
- the antibody of interest is a “N-l” antibody or a “N+l” antibody.
- an injection volume in the one or more capillaries is between about 1 nL and about 10 nL. Tn a specific aspect, an injection volume in the one or more capillaries is about 1 nL.
- the method comprises (a) contacting a sample comprising one or more antibodies of interest with an IdeS protease to digest the sample into antibody fragments, wherein the protease to sample ratio is about 1.25 units of protease to about 1 pg sample; (b) separating antibody fragments by molecular weight and/or charge in one or more capillaries comprising a sieving matrix using capillary electrophoresis; (c) eluting separated antibody fragments from the one or more capillaries; and (d) determining the mass of the eluted antibody fragments by mass spectrometry analysis, thereby detecting and/or discriminating between post- translational modification variants of the antibody of interest, wherein said antibody of interest is maintained in native conditions, and wherein said capillary electrophoresis is in an integrated microfluidic platform.
- This disclosure also provides a method for characterizing a monospecific antibody in a mixture of a bispecific antibody and its monospecific antibody side products.
- the method comprises (a) separating a mixture of a bispecific antibody and its monospecific antibody side products by molecular weight and/or charge in one or more capillaries using capillary electrophoresis; (b) eluting said separated antibody and antibody side products from said one or more capillaries; and (c) determining the mass of said eluted antibody and antibody side products by mass spectrometry, thereby characterizing said monospecific antibody, wherein said monospecific antibody is maintained in native conditions, and wherein said capillary electrophoresis is in an integrated microfluidic platform.
- the method further comprises determining a relative or absolute amount of the monospecific antibody in said mixture.
- the mixture includes an internal standard.
- the one or more capillaries comprise a separation matrix.
- the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
- the monospecific antibody is of isotype IgGl, IgG2, IgG3, IgG4, or mixed isotype.
- the method further comprises characterizing a second monospecific antibody in the mixture.
- an injection volume in the one or more capillaries is between about 1 nL and about 10 nL. In a specific aspect, an injection volume in the one or more capillaries is about 1 nL.
- any of the features or components of embodiments discussed above or herein may be combined, and such combinations are encompassed within the scope of the present disclosure. Any specific value discussed above or herein may be combined with another related value discussed above or herein to recite a range with the values representing the upper and lower ends of the range, and such ranges are encompassed within the scope of the present disclosure.
- FIG. 1 illustrates an exemplary work flow for the separation and detection of post- translational modified antibody fragments by capillary electrophoresis and mass spectral analysis, according to an exemplary embodiment.
- FIG. 2A shows electropherograms evaluating the sensitivity of ZipChip nCE-MS for NISTmAb (IgGl), according to an exemplary embodiment.
- FIG. 2B shows electropherograms evaluating the sensitivity of ZipChip nCE-MS for mAbl (IgGl), according to an exemplary embodiment.
- FIG. 2C shows electropherograms evaluating the sensitivity of ZipChip nCE-MS for mAb2 (IgG4), according to an exemplary embodiment.
- FIG. 2D shows electropherograms evaluating the sensitivity of ZipChip nCE-MS for bsAbl (IgG4), according to an exemplary embodiment.
- FIG. 3 shows mass spectra at the limit of detection (LOD) for NISTmAb, mAbl, mAb2, and bsAbl, according to an exemplary embodiment.
- FIG. 4A shows sensitivity of ZipChip nCE-MS for IgGl, according to an exemplary embodiment.
- FIG. 4B shows sensitivity of ZipChip nCE-MS for IgG4, according to an exemplary embodiment.
- FIG. 4C shows a carryover test of ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 5A shows a charge variant profde of deglycosylated NISTmAb, including two basic variants and two acidic variants, according to an exemplary embodiment.
- FIG. 5B shows a mass spectrum of the acidic 2 variant of NISTmAb, demonstrating Fab glycosylation, according to an exemplary embodiment.
- FIG. 5C shows a zoom-in view of a deglycosylated NISTmAb electropherogram, showing three truncated forms, according to an exemplary embodiment.
- FIG. 5D shows mass spectra of three NISTmAb truncation forms cleaved at (i) Cys223/Asp224, (ii) Lys225/Thr226, and (iii) His227/Thr228, according to an exemplary embodiment.
- FIG. 6 shows the charge variant separation of intact NISTmAb and SEQ ID NO: 1, according to an exemplary embodiment.
- FIG. 7A shows an electropherogram of charge variant analysis of antibody F(ab’)2 and Fc subunits for IdeS treated control and stressed NISTmAb, according to an exemplary embodiment.
- FIG. 7B shows an electropherogram of charge variant analysis of antibody F(ab’)2 subunits for IdeS treated control and stressed NISTmAb, according to an exemplary embodiment.
- FIG. 7C shows an electropherogram of charge variant analysis of antibody Fc subunits for IdeS treated control and stressed NISTmAb, according to an exemplary embodiment.
- FIG. 8A shows a separation of three IgGl mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 8B shows a separation of five bispecific IgG4 mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 8C shows a separation of ten mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 8D shows an identification of co-migrated mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 8E shows an identification of co-migrated mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 9 shows electropherograms for five lots of formulated antibodies manufactured from two different processes, according to an exemplary embodiment.
- FIG. 10 shows mass spectra of main species and basic variant 1 for five lots of mAb3 manufactured with two different processes, according to an exemplary embodiment.
- FIG. 11A shows charge variant separation by SCX-UV, according to an exemplary embodiment.
- FIG. 1 IB shows charge variant separation by ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 12A shows charge variant separation by iCIEF, according to an exemplary embodiment.
- FIG. 12B shows charge variant separation by ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 13A shows an electropherogram of bsAbl with 20 ng injection by ZipChip nCE- MS, according to an exemplary embodiment.
- FIG. 13B shows a lOx zoom-in of an electropherogram of bsAbl with 20 ng injection by ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 13C shows HC*/HC* monospecific mAb impurities at spike-in levels of 1 :500 and 1 :100 in bsAbl by ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 13D shows a zoom-in view of HC*/HC* monospecific mAb impurities at spike-in levels of 1 :500 and 1 : 100 in bsAbl by ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 14 shows mass spectra for HC/HC in a bsAbl sample, HC/HC standard, and half mAb by ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 1 shows mass spectra of HC*/HC* at 0.2% and 1% using ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 16A shows an electropherogram of an “N-1” format antibody using ZipChip nCE- MS, according to exemplary embodiment.
- FIG. 16B shows an electropherogram of an “N+l” format antibody using ZipChip nCE-MS, according to an exemplary embodiment.
- FIG. 17 shows identification of O-glycosylation (Xyl+Gal+Gal+GlcA) in acidic variant 1 of mAb7 using ZipChip nCE-MS, according to an exemplary embodiment.
- mAb Monoclonal antibody
- biAb/bsAb Bispecific antibody
- CE Capillary Electrophoresis
- IEC Ion Exchange Chromatography
- UV Ultra Violet
- ADC Antibody Drug Conjugate
- antibody is intended to refer to immunoglobulin molecules included of four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds (/. ⁇ ?., “full antibody molecules”), as well as multimers thereof (e.g. IgM) or antigen-binding fragments thereof.
- Each heavy chain is included of a heavy chain variable region (“HCVR” or “VH”) and a heavy chain constant region (included of domains CHI, CH2 and CH3).
- the heavy chain may be an IgG isotype.
- the heavy chain is selected from IgGl, IgG2, IgG3 or IgG4.
- the heavy chain is of isotype IgGl or IgG4, optionally including a chimeric hinge region of isotype IgGl/IgG2 or IgG4/IgG2.
- Each light chain is included of a light chain variable region (“LCVR or “VL”) and a light chain constant region (CL).
- VL light chain variable region
- CL light chain constant region
- the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
- Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyterminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the term “antibody” includes reference to both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass.
- the term “antibody” includes antibody molecules prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell transfected to express the antibody.
- For a review on antibody structure see Lefranc et al., JMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains, 27(1) Dev. Comp. Immunol. 55-77 (2003); and M. Potter, Structural correlates of immunoglobulin diversity, 2(1) Surv. Immunol. Res. 27-42 (1983).
- the term antibody also encompasses a “bispecific antibody”, which includes a heterotetrameric immunoglobulin that can bind to more than one different epitope.
- a bispecific antibody which includes a heterotetrameric immunoglobulin that can bind to more than one different epitope.
- One half of the bispecific antibody which includes a single heavy chain and a single light chain and six CDRs, binds to one antigen or epitope, and the other half of the antibody binds to a different antigen or epitope.
- the bispecific antibody can bind the same antigen, but at different epitopes or non-overlapping epitopes.
- both halves of the bispecific antibody have identical light chains while retaining dual specificity.
- Bispecific antibodies are described generally in U.S. Patent App. Pub. No. 2010/0331527 (Dec. 30, 2010).
- the CH3 domain of one heavy chain contains amino acid substitutions that prevent binding to protein A, for example H95R and Y96F substitutions.
- the method of the present invention can be used to detect, identify, quantify, and/or remove monospecific mAb impurities in a sample comprising a bispecific antibody.
- antibody also encompasses alternative antibody formats including, for example, “N-l”, which is a one arm antibody, and “N+l”, where an additional Fab arm is connected using, for example, a G4S linker.
- the method of the present invention can also be used in the analysis of, for example, antibody subunits, antibody fusion proteins, single chain variable fragments (scFvs), diabodies, triabodies, and other antigen-binding proteins or any protein of interest.
- anti gen -binding portion of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen.
- binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al.
- human antibody is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
- the human mAbs of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3.
- human antibody is not intended to include mAbs in which CDR sequences derived from the germline of another mammalian species (e.g., mouse), have been grafted onto human FR sequences.
- the term includes antibodies recombinantly produced in a non-human mammal, or in cells of a non-human mammal.
- the term is not intended to include antibodies isolated from or generated in a human subject.
- ADC antibody-drug conjugate
- a therapeutic moiety such as a cytotoxic agent, a chemotherapeutic drug, immunosuppressant or a radioisotope.
- Cytotoxic agents include any agent that is detrimental to the growth, viability or propagation of cells. Examples of suitable cytotoxic agents and chemotherapeutic agents for forming ADCs are known in the art.
- sample refers to a mixture of molecules that includes at least one polypeptide of interest, such as a monoclonal antibody or a bispecific antibody or fragment thereof, that is subjected to manipulation in accordance with the methods of the invention, including, for example, separating, analyzing, extracting, concentrating or profding.
- polypeptide of interest such as a monoclonal antibody or a bispecific antibody or fragment thereof
- analysis or “analyzing,” as used herein, are used interchangeably and refer to any of the various methods of separating, detecting, isolating, purifying, solubilizing, detecting and/or characterizing molecules of interest (e.g., polypeptides, such as antibodies) and contaminants in antibody preparations. Examples include, but are not limited to, electrophoresis, mass spectrometry, e.g. tandem mass spectrometry, ultraviolet detection, and combinations thereof.
- Chromatography refers to the process of separating a mixture, for example a mixture containing peptides, proteins, polypeptides and/or antibodies, such as monoclonal antibodies. It involves passing a mixture through a stationary phase, which separates molecules of interest from other molecules in the mixture and allows one or more molecules of interest to be isolated.
- isolated refers to a biological component (such as an antibody, for example a monoclonal antibody) that has been substantially separated, produced apart from, or purified away from other biological components in the cell of the organism in which the component naturally occurs or is transgenically expressed, that is, other chromosomal and extrachromosomal DNA and RNA, proteins, lipids, and metabolites.
- Nucleic acids, peptides, proteins, lipids and metabolites which have been "isolated” thus include nucleic acids, peptides, proteins, lipids, and metabolites purified by standard or non-standard purification methods.
- nucleic acids also embraces nucleic acids, peptides, proteins, lipids, and metabolites prepared by recombinant expression in a host cell as well as chemically synthesized peptides, lipids, metabolites, and nucleic acids.
- peptide refers, interchangeably, to a polymer of amino acids and/or amino acid analogs that are joined by peptide bonds or peptide bond mimetics.
- the twenty naturally-occurring amino acids and their single-letter and three-letter designations are as follows: Alanine A Ala; Cysteine C Cys; Aspartic Acid D Asp; Glutamic acid E Glu; Phenylalanine F Phe; Glycine G Gly; Histidine H His; Isoleucine I He; Lysine K Lys; Leucine L Leu; Methionine M Met; Asparagine N Asn; Proline P Pro; Glutamine Q Gin; Arginine R Arg; Serine S Ser; Threonine T Thr; Valine V Vai; Tryptophan W Trp; and Tyrosine Y Tyr.
- a peptide is an antibody or fragment or part thereof, for example, any of the fragments or antibody chains listed above.
- the peptide may be post-translationally modified.
- protein of interest and/or “target protein of interest” refer to any protein to be separated and/or detected with the methods provided herein. Suitable proteins of interest include antibodies, for example monoclonal antibodies, and fragments thereof.
- Detect and “detection” have their standard meaning, and are intended to encompass detection including the presence or absence, measurement, and/or characterization of a protein of interest, such as a mAb or fragment thereof.
- standard and/or “internal standard” refer to a well- characterized substance of known amount and/or identity (e.g., known molecular weight, electrophoretic mobility profile) that can be added to a sample and both the standard and the molecules in the sample, on the basis of molecular weight or isoelectric point by electrophoresis). A comparison of the standard then provides a quantitative or semi -quantitative measure of the amount of analyte, such as mAb or fragments thereof present in the sample.
- analyte such as mAb or fragments thereof present in the sample.
- Contacting includes bringing together at least two substances in solution or solid phase, for example contacting a sample with an enzyme, such as a protease.
- corresponding is a relative term indicating similarity in position, purpose or structure, and may include peptides of identical structure but for the presence or absence of a post-translational modification.
- mass spectral signals in a mass spectrum that are due to corresponding peptides of identical structure but for the presence or absence of a post-translational modification are "corresponding" mass spectral signals.
- a mass spectral signal due to a particular peptide is also referred to as a signal corresponding to the peptide.
- a particular peptide sequence or set of amino acids can be assigned to a corresponding peptide mass.
- fragment peptide or “peptide fragment,” as used herein, refer to a peptide that is derived from the full-length polypeptide, such as a protein and/or monoclonal antibody, through processes including fragmentation, enzymatic proteolysis, or chemical hydrolysis.
- proteolytic peptides include peptides produced by treatment of a protein with one or more proteases, such as IdeS protease.
- a fragment peptide, or peptide fragment can be a digested peptide.
- Mass spectrometry refers to a method in which a sample is analyzed by generating gas phase ions from the sample, which are then separated according to their mass-to-charge ratio (m/z) and detected.
- Methods of generating gas phase ions from a sample include electrospray ionization (ESI), matrix-assisted laser desorption-ionization (MALDT), surface-enhanced laser desorption-ionization (SELDI), chemical ionization, and electron-impact ionization (El).
- Separation of ions according to their m/z ratio can be accomplished with any type of mass analyzer, including quadrupole mass analyzers (Q), time-of-flight (TOF) mass analyzers, magnetic sector mass analyzers, 3D and linear ion traps (IT), orbitrap mass analyzer, Fourier- transform ion cyclotron resonance (FT-ICR) analyzers, and combinations thereof (for example, a quadrupole-time-of- flight analyzer, or Q-TOF analyzer).
- Q quadrupole mass analyzers
- TOF time-of-flight
- IT linear ion traps
- orbitrap mass analyzer orbitrap mass analyzer
- Fourier- transform ion cyclotron resonance (FT-ICR) analyzers for example, a quadrupole-time-of- flight analyzer, or Q-TOF analyzer.
- the sample Prior to separation, the sample may be subjected to one or more dimensions of chromatographic separation, for example, one or more dimensions of
- Tandem mass spectrometry or MS/MS is a technique to break down selected ions (precursor ions) into fragments (product ions) The fragments then reveal aspects of the chemical structure of the precursor ion.
- tandem mass spectrometry once samples are ionized (for example by ESI, MALDI, El, etc.) to generate a mixture of ions, precursor ions, for example peptides from a digest of a specific mass-to-charge ratio ( /z) are selected (MSI) and then fragmented (MS2) to generate product ions for detection.
- Typical tandem MS instruments include QqQ, QTOF, and hybrid ion trap/FTMS, etc.
- tandem mass spectrometry is protein identification.
- the first mass analyzer isolates ions of a particular m/z value that represent a single species of peptide among many introduced into and then emerging from the ion source. Those ions are then accelerated into a collision cell containing an inert gas such as argon to induce ion fragmentation. This process is designated collisionally induced dissociation (CID) or collisionally activated dissociation (CAD). The m/z values of fragment ions are then measured in a 2 nd mass analyzer to obtain amino acid sequence information.
- CID collisionally induced dissociation
- CAD collisionally activated dissociation
- references to a mass of an amino acid mean the monoisotopic mass or average mass of an amino acid at a given isotopic abundance, such as a natural abundance.
- the mass of an amino acid can be skewed, for example, by labeling an amino acid with an isotope. Some degree of variability around the average mass of an amino acid is expected for individual single amino acids based on the exact isotopic composition of the amino acid.
- the masses, including monoisotopic and average masses for amino acids are easily obtainable by one of ordinary skill the art.
- references to a mass of a peptide means the monoisotopic mass or average mass of a peptide at a given isotopic abundance, such as a natural abundance.
- the mass of a peptide can be skewed, for example, by labeling one or more amino acids in the peptide with an isotope. Some degree of variability around the average mass of a peptide is expected for individual single peptides based on the exact isotopic composition of the peptide. The mass of a particular peptide can be determined by one of ordinary skill the art.
- CE, MS, and CE-MS can be performed under native conditions (nCE-MS).
- native conditions can include performing capillary electrophoresis and/or mass spectrometry under conditions that preserve non-covalent interactions in an analyte, in contrast to, for example, reducing and/or denaturing conditions.
- Native capillary electrophoresis and/or mass spectrometry is an approach to study intact biomolecular structure in the native or near-native state.
- the term “native” refers to the biological status of the analyte in solution prior to subjecting to separation and/or ionization. Several parameters, such as pH and ionic strength, of the solution containing the biological analytes can be controlled to maintain the native folded state of the biological analytes in solution.
- Therapeutic antibodies are a major class of biopharmaceuticals that have been developed as treatments for a variety of therapeutic areas including infectious diseases (Sparrow etal., 2017, Bull. World Health Organ., 95(3):235-237), inflammation and immunology (Chan et al., 2010, Nat. Rev. Immunol., 10(50):301-316), oncology (Scott et al., 2012, Nat. Rev. Cancer., 12(4):278-287), hematology (Cuesta-Mateos et al., 2017, Front. Immunol., 8: 1936), ophthalmology (Rodrigues etal., 2009, Prog. Retin.
- mAbs immunoglobulin G subclasses, such as IgGl and IgG4, have attracted the most attention, because of their simpler structures and longer half-lives than those of other subclasses.
- bispecific antibodies in which the two heavy chains and light chains may be different, and other IgG-based molecules in alternative formats, such as those with addition and removal of the antigen-binding fragment (Fab) arm, have also been created to achieve advantageous properties such as the ability to interact with multiple therapeutic targets (Labrijn et al., 2019, Nat. Rev. Drug Discov., 18(8):585-608; Seung et aL, 2022, Nature, 603(7900):328-334; Spiess et al., 2015, Mol.
- bsAbs can achieve high target specificity through one paratope and recruitment of tumor killing agents through the other paratope (Runcie et al., 2018, Afo/. Med., 24(l):50).
- Characterization of antibody variants is important in order to identify their potential impact on safety, potency, and stability of a potential therapeutic antibody. For example, to be considered for approval by regulatory agencies, extensive characterization of the molecule must be performed. Tn drug products comprising mixtures of antibodies, characterization of the absolute or relative amounts of each antibody must be determined. Because aggregates and fragments may potentially affect immunogenicity and potency, their levels are typically monitored during lot release, stability, and characterization. Furthermore, primary degradation pathways for the molecule and product related impurities and variants are determined.
- PTMs post-translational modifications
- modifications include glycosylation, asparagine deamidation, aspartic acid isomerization and cyclization, methionine and tryptophan oxidation, and lysine glycation, among others (Liu et al., 2008, J. Pharm. Set., 97(7): 2426-2447).
- Mass spectrometry has been extensively used to study PTMs at the peptide, subunit, and intact levels (Zhang et al., 2014, EEBS Lett., 588(2):308-317).
- Peptide mapping wherein therapeutic antibodies are digested with enzymes, can be used to monitor multiple PTMs simultaneously and have been widely adopted (Rogstad et al., 2017, J. Am. Soc. Mass Spectrom., 28(5):786-794). Additionally, intact mass analysis of therapeutic antibodies at both the subunit and intact levels has also been performed (Jin etal., 2019, MAbs, 11(1): 106-115).
- Charge variant analysis is critical for understanding the structure of biotherapeutics during drug development and product release (Du et al.).
- the charge variant profile can be characterized by several analytical techniques, including imaged capillary isoelectric focusing (iCIEF) and cation exchange chromatography (CEX), to enable relative quantification of charge variants.
- iCIEF imaged capillary isoelectric focusing
- CEX cation exchange chromatography
- the iCIEF technique separates charge species according to the isoelectric point (pl) (Salas-Solano etal., 2011, Chromatographia, 73(11): 1137-1144).
- CEX is a chromatographic technique that separates species according to surface charge
- strong cation exchange (SCX) is a common method used for therapeutic antibody analysis (Fekete et al., 2015, J. Pharm.
- ZipChip is an integrated microfluidic capillary electrophoresis (CE) system that can be directly coupled with the MS interface, and has been used to analyze small molecules in media, monosaccharides and oligosaccharides (Ribeiro da Silva et al., 2021, J. Chromatogr. A, 1651 :462336; Khatri et al., 2017, Anal. Chem., 89(12):6645-6655); peptides for antibody protein sequence confirmation and proteomic analysis (Khatri etal.; Dykstra et al., 2021, J. Am. Soc. Mass Spectrom., 32(8): 1952-1963; Cao et al., 2021, J.
- CE microfluidic capillary electrophoresis
- the charge variants with more positive charges migrate faster and elute earlier in the native BGE (pH ⁇ pl of antibody), whereas variants with fewer positive charges migrate slowly in the separation channel under the electric field. Therefore, in a typical antibody charge separation profile, basic variants elute first, followed by the main species and acid variants. Additionally, the ZipChip interface is compatible with common formulation buffer components containing anionic or nonionic detergents for easy sample preparation. [00136] Disclosed herein is a highly sensitive, high-resolution microfluidic nCE-MS method for detecting and/or discriminating between variants of an antibody of interest, such as a therapeutic antibody, in a sample by a physical parameter, such as mass and/or charge.
- a physical parameter such as mass and/or charge.
- the method may be used, for example, for antibody charge variant and impurity analysis, and for the quick identification of antibody charge variants for forced degradation and long-term stability studies.
- the sensitivity was first evaluated with three types of therapeutic antibodies. Additionally, antibody samples from different manufacturing processes and lots, as well as the antibody cocktail, were analyzed with the nCE-MS method. Comparative analysis of charge variant profiles was performed for the nCE-MS, SCX and iCIEF methods. The high sensitivity of the nCE-MS method enabled detection of fragments with very low abundance in the antibody sample and homospecific mAb impurities in the bsAb sample. Finally, new antibody modalities were evaluated with the nCE-MS method.
- a sample that includes an antibody of interest is resolved or separated by using capillary electrophoresis, for example on one or more capillaries of a CE- system.
- the sample is resolved or separated by molecular weight and charge. For example, using separation by mass and charge, or m/z ratio, fragments with the same mass but different charges can be resolved. Similarly, using separation by mass and charge, or m/z ratio, fragments with the same charge but different masses can be resolved.
- the method includes liberating fragments of an antibody of interest, such as a monoclonal antibody (mAb), for example by contacting the sample comprising one or more antibodies of interest with a protease to digest the sample.
- a protease is IdeS protease. Once digestion, either partial or full, is conducted, antibody fragments can be separated by molecular weight and/or charge in one or more capillaries using capillary electrophoresis.
- the separated antibody fragments can be eluted from the one or more capillaries and the mass of the eluted antibody fragments determined by mass spec analysis to detect and/or discriminate between post-translational modification variants of the antibody of interest, for example by detection and/or determination of the PTM profile of the fragments of the antibody of interest.
- the antibody fragments include one or more of an F(ab’)2 or Fc antibody subunit, for example as digested from the intact antibody using a protease, such as the IdeS protease.
- the antibody of interest is a monoclonal antibody, such as a currently used therapeutic antibody or one undergoing evaluation, including novel monoclonal antibodies.
- the monoclonal antibody of interest is part of an antibody drug conjugate (ADC).
- ADC antibody drug conjugate
- the antibody fragments are separated by charge and the method is a method of detecting and/or discriminating between charge variants of the antibody of interest.
- the antibody fragments are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of the antibody of interest.
- the antibody fragments are separated by charge and molecular weight and the method is a method of detecting and/or discriminating between charge and molecular weight variants of the antibody of interest.
- the method includes determining a relative or absolute amount of the post-translational modification variants of an antibody of interest in a sample, for example from the antibody fragments.
- the post-translational modification is one or more of deamidation, oxidation, glycation, disulfide formation, N-terminal pyroglutamate formation, C- terminal lysine removal, high mannose glycosylation, and O-glycosylation.
- the sample is resolved or separated within a single capillary. In certain embodiments, the sample is resolved or separated within multiple capillaries, for example in parallel.
- separation by molecular weight the smaller the fragment of an antibody, the further within a capillary it would be expected to travel over a given period of time. In addition, one would expect differences in the charge of antibody fragments to be subjected to different travel times depending on the charge.
- the sample may contain multiple, such as at least 2, at least 3, at least 4, at least 5 or more sets of antibody fragments from multiple antibodies of interest.
- the method further includes determining a relative or absolute amount of the variants of the antibody fragments in a sample, for example by measurement of peak height or area, which corresponds to the amount of antibody fragment in the sample.
- the antibody of interest comprises a bispecific monoclonal antibody.
- the sample includes one or more internal standards, for example a ladder of molecular weight standards, a ladder of isoelectric point standards, or even a standard used as a baseline or benchmark for determining the amount of an antibody fragments of interest in the sample.
- the method includes separating protein components of a sample with two or more mAbs of interest, such as 2, 3, 4, 5, 6, 7, 8, 9 10 or even more, mAbs of interest, by charge in one or more capillaries using capillary electrophoresis
- a charge based profile or fingerprint of the antibody of interest can be created, for example of the antibody of interest alone for comparison with a charge based profile or fingerprint of the antibody in the mixture, for example a charge based profile or fingerprint corresponding to the post-translational modification. This comparison can then be used to determine if the antibody of interest changes in the mixture. This profile or fingerprint comparison can be done for any or all of the antibodies of interest in the mixture.
- Samples for use in the disclosed methods can be heterogeneous, containing a variety of components, i.e. different proteins.
- the sample can be homogenous, containing one component or essentially one component of multiple charge or molecular weight species.
- Pre-analysis processing may be performed on the sample prior to detecting the antibody of interest, such as a mAb or multiple mAbs.
- the sample can be subjected to a lysing step, denaturation step, heating step, purification step, precipitation step, immunoprecipitation step, column chromatography step, centrifugation, etc.
- the separation of the sample and immobilization may be performed on native substrates.
- the sample may be subjected to denaturation, for example, heat and/or contact with a denaturizing agent.
- Denaturizing agents are known in the art.
- the sample may be subjected to non-reducing conditions.
- the sample may be subjected to reducing conditions, for example, by contacting the sample with one or more reducing agents. Reducing agents are knowns in the art.
- the capillary may include a separation matrix, which can be added in an automated fashion by the apparatus and/or system.
- the sample is loaded onto a stacker matrix prior to separation.
- the separation matrix in one embodiment, is a size separation matrix, and has similar or substantially the same properties of a polymeric gel, used in conventional electrophoresis techniques.
- Capillary electrophoresis in the separation matrix is analogous to separation in a polymeric gel, such as a polyacrylamide gel or an agarose gel, where molecules are separated on the basis of the size of the molecules in the sample, by providing a porous passageway through which the molecules can travel.
- the separation matrix permits the separation of molecules by molecular size because larger molecules will travel more slowly through the matrix than smaller molecules.
- the one or more capillaries comprise a separation matrix.
- the sample containing an antibody of interest is separated or resolved based on molecular weight.
- the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
- protein components of a sample are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of an antibody of interest.
- antibody fragments of a sample are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of a contaminating protein of interest.
- a wide variety of solid phase substrates are known in the art, for example gels, such as polyacrylamide gel.
- resolving one or more proteins of interest includes electrophoresis of a sample in a polymeric gel. Electrophoresis in a polymeric gel, such as a polyacrylamide gel or an agarose gel separates molecules on the basis of the molecule's size.
- a polymeric gel provides a porous passageway through which the molecules can travel. Polymeric gels permit the separation of molecules by molecular size because larger molecules will travel more slowly through the gel than smaller molecules.
- the sample containing a protein of interest is separated or resolved based on the charge of the components of the sample.
- protein components of a sample are separated by charge and the method is a method of detecting and/or discriminating between charge variants of a monoclonal antibody of interest.
- fragments of a sample are separated by charge and the method is a method of detecting and/or discriminating between charge variants of an antibody of interest of interest.
- an internal standard can be a purified form of the antibody of interest itself or fragment thereof, which is generally made distinguishable from the antibody of interest in some way.
- Methods of obtaining a purified form of the antibody of interest itself or fragment thereof can include, but are not limited to, purification from nature, purification from organisms grown in the laboratory (e.g., via chemical synthesis), and/or the like.
- the distinguishing characteristic of an internal standard can be any suitable change that can include, but is not limited to, dye labeling, radiolabeling, or modifying the mobility of the standard during the electrophoretic separation so that it is separated from the antibody of interest.
- a standard can contain a modification of the antibody of interest itself or fragment thereof that changes the charge, mass, and/or length (e.g., via deletion, fusion, and/or chemical modification) of the standard relative to the antibody of interest itself or fragment thereof.
- the antibody of interest itself or fragment thereof and the internal standard can each be labeled with fluorescent dyes that are each detectable at discrete emission wavelengths, thereby allowing the protein of interest and the standard to be independently detectable.
- an internal standard is different from the antibody of interest itself or fragment thereof but behaves in a way similar to or the same as the antibody of interest itself or fragment thereof, enabling relevant comparative measurements.
- the sample can be loaded into one end of the capillary.
- the sample is loaded into one end of the capillary by hydrodynamic flow.
- the sample can be loaded into one end of the capillary by hydrodynamic flow, such that the capillary is used as a micropipette.
- the sample can be loaded into the capillary by electrophoresis, for example, when the capillary is gel fdled and therefore more resistant to hydrodynamic flow.
- the capillary can include any structure that allows liquid or dissolved molecules to flow.
- the capillary can include any structure known in the art, so long as it is compatible with the methods.
- the capillary is a bore or channel through which a liquid or dissolved molecule can flow.
- the capillary is a passage in a permeable material in which liquids or dissolved molecules can flow.
- the capillary includes any material that allows the detection of the protein of interest within the capillary.
- the capillary includes any convenient material, such as glass, plastic, silicon, fused silica, gel, or the like.
- the method employs a plurality of capillaries. A plurality of capillaries enables multiple samples to be analyzed simultaneously.
- the capillary can vary as to dimensions, width, depth and cross-section, as well as shape, for example being rounded, trapezoidal, rectangular, etc.
- the capillary can be straight, rounded, serpentine, or the like.
- the length of the fluid path depends in part on factors such as sample size and the extent of sample separation required to resolve the protein of interest.
- the capillary includes a tube with a bore.
- the method employs a plurality of capillaries. Suitable sizes include, but are not limited to, capillaries having internal diameters of about 10 to about 1000 pm, although more typically capillaries having internal diameters of about 25 to about 400 pm can be utilized. Smaller diameter capillaries use relatively low sample loads while the use of relatively large bore capillaries allows relatively high sample loads and can result in improved signal detection.
- the capillaries can have varying lengths. Suitable lengths include, but are not limited to, capillaries of about 1 to 20 cm in length, although somewhat shorter and longer capillaries can be used. In some embodiments, the capillary is about 1, 2, 3, 4, 5, or 6 cm in length. Longer capillaries typically result in better separations and improved resolution of complex mixtures. Longer capillaries can be of particular use in resolving low abundance proteins of interest.
- the capillaries are composed of fused silica, although plastic capillaries and PYREX (i.e., amorphous glass) can be utilized. As noted above, the capillaries do not need to have a round or tubular shape. Other shapes, so long as they are compatible with the methods described herein, may also be used.
- the capillary can be a channel. In some embodiments, the method employs a plurality of channels. In some embodiments, the capillary can be a channel in a microfluidic device.
- Microfluidics employ channels in a substrate to perform a wide variety of operations.
- the microfluidic devices can include one or a plurality of channels contoured into a surface of a substrate.
- the microfluidic device can be obtained from a solid inert substrate, and in some embodiments in the form of a chip.
- the dimensions of the microfluidic device are not critical, but in some embodiments the dimensions are on the order of about 100 pm to about 5 mm thick and approximately about 1 centimeter to about 20 centimeters on a side.
- Suitable sizes include, but are not limited to, channels having a depth of about 5 pm to about 200 pm, although more typically having a depth of about 20 pm to about 50 pm can be utilized. Smaller channels, such as micro or nanochannels can also be used, so long as they are compatible with the methods.
- the antibody fragments may be obtained from an antibody of interest, such as a monoclonal antibody.
- the antibody fragments may be prepared by reduction, enzymatic digestion, denaturation, fragmentation, chemical cleavage or a combination thereof.
- the methods disclosed herein are applicable to any antibody isotype, such as IgGl, IgG2, IgG3, IgG4, or mixed isotype.
- Reduction is to reduce disulfide bonds into two thiols in a 3-dimensional protein, such as a monoclonal antibody.
- Reduction can be performed by heat-denaturing, adding a surfactant, or adding a denaturing agent, e.g., guanidine HC1 (6M), in the presence of a reducing agent, e.g. TCEP-HC1.
- Enzymatic degradation is a digestion of the protein with a protease, e.g., trypsin or Achromobacter protease I (Lys-C).
- the glycoprotein can be denatured by heat or chemicals, or a combination thereof.
- Fragmentation involves cleaving protein portions of a single or multi-subunit protein, such as a monoclonal antibody, with physical, biological or chemical methods.
- an immunoglobulin degrading enzyme from S. pyogenes (IdeS) is commonly used for antibody subunit fragmentation.
- an antibody in a sample can be treated and prepared by reduction, enzymatic degradation, denaturation or fragmentation prior to contacting with the hydrophilic enrichment substrate.
- the methods provide a novel chromatographic method to characterize the post-translational modification of antibodies, e.g., monoclonal antibody (mAb) therapeutics, by means of fragments.
- the samples at any intervening step may be concentrated, desalted or the like.
- the methods further comprise detecting the post-translationally modified antibody fragments, for example using the UY signal from the peptide portion of the post-translationally modified antibody fragments. This may be done for fractions of a sample and allows the selection of specific fractions for further analysis, for example mass spec (MS) analysis.
- MS mass spec
- the detection step comprises mass spectrometry or liquid chromatography-mass spectrometry (LC-MS). In applications of mass spectrometry for the analysis of biomolecules, the molecules are transferred from the liquid or solid phases to gas phase and to vacuum phase.
- MALDI matrix-assisted laser desorption ionization
- ESI electrospray ionization
- Aspects of the use of these methods, and sample preparation requirements, are known to those of ordinary skill in the art. In general, ESI is more sensitive, while MALDI is faster. Significantly, some peptides ionize better in MALDI mode than ESI, and vice versa (Genome Technology, June 220, p 52).
- the extraction channel methods and devices of the instant invention are particularly suited to preparing samples for MS analysis, especially biomolecule samples such as post- translationally modified antibody fragments.
- An important advantage of the invention is that it allows for the preparation of an enriched sample that can be directly analyzed, without the need for intervening process steps, e.g., concentration or desalting.
- ESI is performed by mixing the sample with volatile acid and organic solvent and infusing it through a conductive needle charged with high voltage.
- the charged droplets that are sprayed (or ejected) from the needle end are directed into the mass spectrometer, and are dried up by heat and vacuum as they fly in. After the drops dry, the remaining charged molecules are directed by electromagnetic lenses into the mass detector and mass analyzed.
- the eluted sample is deposited directly from the capillary into an electrospray nozzle, e.g., the capillary functions as the sample loader.
- the capillary itself functions as both the extraction device and the electrospray nozzle.
- the analyte molecules e.g., proteins
- the samples are dried and inserted into the mass spectrometer, and typically analyzed via time-of-flight (TOF) detection.
- TOF time-of-flight
- the eluted sample is deposited directly from the capillary onto the metal target, e g , the capillary itself functions as the sample loader.
- the extracted analyte is deposited on a MALDI target, a MALDI ionization matrix is added, and the sample is ionized and analyzed, e.g., by TOF detection.
- other ionization modes are used e.g. ESLMS, turbospray ionization mass spectrometry, nanospray ionization mass spectrometry, thermospray ionization mass spectrometry, sonic spray ionization mass spectrometry, SELDLMS and MALDI-MS.
- ESLMS turbospray ionization mass spectrometry
- nanospray ionization mass spectrometry nanospray ionization mass spectrometry
- thermospray ionization mass spectrometry e.g., sonic spray ionization mass spectrometry
- SELDLMS sonic spray ionization mass spectrometry
- MALDI-MS MALDI-MS
- the sample matrix in many applications must have low ionic strength, or reside within a particular pH range, etc.
- Tn ESI, salt in the sample can prevent detection by lowering the ionization or by clogging the nozzle. This problem is addressed by presenting the analyte in low salt and/or by the use of a volatile salt.
- the analyte should be in a solvent compatible with spotting on the target and with the ionization matrix employed.
- the method further includes identifying the antibody fragments, for example the sequence of the antibody fragments.
- the method further includes identifying the post-translational modification present on the antibody fragments.
- the method further includes post-translational modification profiling of the antibody of interest.
- the method further includes post-translational modification mapping of post- translational modification hotspots by reduced peptide mapping LC-MS/MS analysis.
- ProteinSimple methyl cellulose (MC) solution at 0.5% and 1%, Pharmalytes (broad range pH 3-10), and pl markers were purchased from VWR International (Radnor, PA).
- ZipChip HRN chips with a 22 cm separation channel and a native assay kit with Native Antibodies background electrolyte (BGE) were acquired from 908 Devices (Boston, MA).
- NISTmAb sample was treated with PNGase F (1 IUB milliunit per 10 pg of protein) at 45 °C in Milli-Q water for 1 hour.
- HC/HC and HC*/HC* concentration of each bsAb stock solution and two homospecific mAb impurities (referred to as HC/HC and HC*/HC*) were measured based on the UV absorbance at 280 nm and the corresponding extinction coefficient.
- a series of solutions were prepared through mixture of bsAb with percentages of homospecific mAb impurities at 0.2% and 1.0%.
- NIST IgGl mAb (5 mg/mL, pH 6.0) was incubated at 45 °C for 0, 1, 4, 8, 15 and 28 days.
- IdeS treatment For subunit analysis, each NISTmAb sample was diluted to 2 mg/mL with Milli-Q water. Then 125 units of IdeS (Promega) was added to 100 pg of mAb at enzyme/ anti body ratio of 1 .25/1 . The mixture was incubated at 37 °C with shaking at 600 rpm for 30 minutes to generate F(ab’)2 and Fc fragments. Control and stressed samples after each study/treatment were stored immediately at -20 °C. A summary of the method is shown in FIG. 1.
- nCE-MS Native microfluidic CE-MS
- the intact mass analysis of antibodies and charge variants was conducted with the ZipChip CE interface (908 Devices, Boston, MA) coupled to an Exactive Plus EMR Orbitrap mass spectrometer (Thermo Scientific, Bremen, Germany).
- Samples were loaded on the sample well of a microfluidic chip by a model 840 autosampler with a pressure assistance start time at 0.2 min and a replicate delay of 30 seconds.
- the injection volume was 1 nL.
- Charge variants were separated in the separation channel of the microfluidic chip by using Native Antibodies BGE, 3.8% DMSO, pH ⁇ 5.5, under a field strength of 650 V/cm for 15 min.
- MS data acquisition was performed through a full scan at a resolution of 17,500 in positive mode with a scan range of 1000-10000 m/z, in-source CID at 100 eV, AGC at 3e6, maximum injection time of 50 ms, and 3 microscans.
- the ESI parameters were set with spray voltage at 0, capillary temperature at 300 °C, S-lens at 150, sheath gas at 2, auxiliary gas at 0, and trapping gas at 1.
- Samples were subsequently pre-focused for 1 minute at 1.5 kV, then subjected to a 7.0 minute focusing period at 3 kV with 100 mM sodium hydroxide as the catholyte and 80 mM phosphoric acid as the anolyte, both in 0.1% (w/v) methyl cellulose. Proteins were monitored during focusing according to the UV absorbance at 280 nm with a scanning charge-coupled device (CCD) camera. Electropherograms were generated with CCD detection of UV light absorption across the separation capillary.
- CCD scanning charge-coupled device
- CE capillary electrophoresis
- MS mass spectrometry
- nCE-MS combined with nanospray ESI provides ultra-high sensitivity in detecting low abundant charge variant species.
- the method sensitivity of nCE-MS in analyzing various types of IgG was evaluated by separate injection of different amounts of antibody from 0.01 ng to 1 ng on the chip.
- the antibody charge separation profile was extracted with BPCs with mass range from 4000 to 9000 m/z, as shown in FIG. 2.
- a limit of detection (LOD) of 0.01 ng was achieved, as shown in FIG. 2A, FIG. 2B, and FIG. 4A.
- the MS signal was detected down to 0.02 ng and 0.05 ng, respectively, as shown in FIG. 2C, FIG. 2D, and FIG. 4B.
- the mass spectra of the main species of each antibody showed a high signal-to-noise ratio, thus demonstrating the excellent sensitivity of the nCE-MS method, as shown in FIG. 3.
- the charge variant profile was directly observed at the LOD for all four mAbs. No run-to-run injection carryover was observed for the nCE-MS method, as shown in FIG. 4C.
- NISTmAb In order to assess the sensitivity of the method for additional fragmented and truncated species, a forced degradation study and subunit digestion study was conducted using NISTmAb.
- the NTSTm Ab reference standard and its heat-stressed forms were analyzed following incubation at 45 °C for up to 28 days. Samples with different incubation times were cleaved by IdeS digestion to generate F(ab’)2 or Fc associated subunit species.
- the intact mass analysis of both control and stressed antibodies was conducted using a universal Zipchip nCE-MS method.
- the PTM hotspots were identified by reduced peptide mapping LC-MS/MS analysis to elucidate the elevated charge variants under stressed conditions.
- Intact mass data was processed by PMi- Intact software.
- the elevated charge variants were allocated to F(ab’)2 or Fc by the subunit charge variant analysis.
- Reduced peptide mapping data was processed by BioPharma Finder 3.0 and Skyline-daily 4.2 for PTMs identification and quantification, respectively.
- F(ab’)2 and Fc were well separated by the universal nCE-MS method. All minor peaks were identified, as shown in FIGs. 7A-7C. New charge variants resulting from 28-day incubation are indicated in blue shaded regions. Two basic variants with 1 and 2 unprocessed C- terminal lysines were located in the Fc region (FIG. 7C). The basic variant 3, resulting from Fab cleavage at His 227 /Thr 228 in stressed sample (45 °C, D28), was identified as F(ab’)2 basic variant (b* 1) in FIG. 7B. All other Fab cleavage sites were found in the acid region of F(ab’)2 and in the same order as those were identified during intact antibody analysis.
- FIG. 8A Three IgGl mAbs in mixture 1 (FIG. 8A) and five IgG4 bispecific mAbs in mixture 2 (FIG. 8B) were well separated by the ZipChip nCE-MS method of the present invention, which can be applied for intact mass analysis of co-formulated drugs. Even if two antibodies comigrated together (blue shaded area in FIG. 8C), those can be identified individually from native MS data, as shown in FIG. 8D and FIG. 8E. FIG. 8E shows the convoluted spectra. Besides high-resolution charge variant analysis of a single antibody, the ZipChip nCE-MS method can also be used as a high-throughput and high-sensitivity approach for intact mass analysis of antibody mixture and ADCs.
- nCE-MS is a new method for charge variant analysis, in contrast to SCX and iCIEF, which are commonly used as characterization and release assays.
- SCX and iCIEF which are commonly used as characterization and release assays.
- the nCE-MS method was first compared to SCX with UV detection.
- Three types of antibodies including IgGl NISTmAb, IgG4 mAb2, and bispecific IgG4 bsAb2 were used for this comparison.
- the charge variant separation profiles of these three types of antibodies are shown in FIG. 11 between the SCX-UV method using a pH gradient and nCE-MS. Comparable high-resolution charge variant separations of all types of IgG were obtained between platforms, including the same number of basic and acidic variants.
- the nCE-MS method enabled high resolution charge variant separation with only a 1 ng injection. More importantly, each charge variant was directly identified by online MS analysis.
- the SCX-UV method generally uses MS-incompatible salts, and often requires either fraction collection or two-dimensional liquid chromatography coupled with MS to elucidate the PTMs in the charge variants (Alvarez et al. 2011, Anal. Biochem. 419(1): 17-25; Jaag et al, 2021, J. Chromatogr. A, 1636:461786).
- SCX-nMS SCX coupled to native MS
- SCX-nMS charge variant analysis of mAbs
- Similar charge variant profiles have been obtained between SCX-nMS and nCE-MS analysis (Fussl et al., 2Q2Q, Anal. Chem., 92(7):5421-5438).
- sample amounts of approximately 50 pg are often required for SCX-nMS with post-column flow splitting to enhance sensitivity, and to provide the same detection of truncated species and Fab glycosylation species shown in FIG.
- iCIEF separates analytes according to intrinsic pl
- nCE-MS method is based on capillary zone electrophoresis that takes into account both the solvated charge and size of the analytes.
- nCE-MS is a highly sensitive, high- resolution approach for the characterization of antibody charge variants, and the similarity in electropherograms between iCIEF and nCE-MS may aid in the identification of antibody charge variants for iCIEF assays.
- nCE-MS iCIEF and SCX assays are performed with UV detection, which can directly enable quantification of charge variants
- nCE-MS relies on BPCs from MS and provides the relative quantification.
- the relative quantification is also impacted by the differential ionization efficiency among acidic, main, and basic species.
- the SCX-nMS method with flow splitting to a UV detector can be used to quantitatively measure the percentages of charge variants (Yan et al., 2018).
- Example 5 Bispecific antibody impurity analysis
- Impurities in bsAb therapeutics are a subject of interest for the pharmaceutical industry (Yan et al., 2019, Anal. Chem., 91(17): 11417-11424).
- the bsAb of interest comprised two identical light chains and two different heavy chains, HC and HC* (Smith et al., 2015, Sci. Rep., 5(1): 17943; Tustian et al., 2016, MAbs, 8(4): 828-838).
- homospecific mAb impurities which are composed of two identical light chains and two identical heavy chains (either HC or HC*), are removed during purification in the manufacturing process, some residual homospecific mAb impurities (referred to as HC/HC and HC*/HC*) remain in the desired bsAb product (Li, 2019, Protein Expr. Purif., 155(112-119). Quantification of these homospecific mAb species is necessary to ensure product safety and efficacy.
- the nCE-MS method was used for the analysis of the bispecific IgG4 bsAbl, as shown in FIG. 13A.
- bispecific antibody common charge variants were detected, including antibody with one or two unprocessed C-terminal lysine residues in the basic variants, and deamidation, glycation, as well as one or two N-acetylneuraminic acid residues in the acidic variants, as shown in Table 5.
- HC/HC and HC*/HC* impurities and bsAb should be separated in the nCE-MS method.
- the HC*/HC* impurity was detected at a level of 0.2% in spiked bsAbl samples, as shown in FIG. 13C and FIG. 15.
- the high sensitivity of the nCE-MS method was also demonstrated by the observation of separate peaks for charge variants of HC*/HC* impurity at a level of 1%, as shown in FIG. 13D. With this method, the HC*/HC* impurity was determined to be below 0.2%, if any, in the bsAbl sample.
- nCE-MS can analyze the charge variants of new formats of antibody derivatives.
- mAb6 is a therapeutic antibody in “N-l” format where one Fab arm is removed, and it has Gin in the N-terminus of the HC.
- Gin would be converted into pyroglutamate.
- a small percentage of Gin is often found to be unconverted, thus resulting in a basic charge variant relative to the main species, which is a mAb with complete conversion of Gin to pyroglutamate (Liu et al., 2019, J. Pharm. Sci., 108(10): 3194-3200).
- nCE-MS analysis revealed eight species, including four basic variants and three acidic variants, as shown in FIG. 16A and Table 6.
- PTMs including one or two unprocessed C-terminal Lys residues, one unconverted Gin, and a combination of one unprocessed C-terminal Lys residue and one unconverted Gin were observed.
- Three acidic variants included PTMs such as deamidation, glycation, and one to three N-acetylneuraminic acid residues.
- nCE-MS analysis revealed five species, including two basic variants and two acidic variants, as shown in FIG. 16B and Table 7.
- the basic variants were attributed mainly to one or two unprocessed C-terminal Lys residues and N-terminal pyroglutamate formation.
- the acidic variants in addition to commonly observed PTMs such as deamidation and glycation, mass differences matching O- glycosylation were also detected, as shown in FIG. 17.
- the O-glycan has a structure of Xyl+Gal+Gal+GlcA, which is a common O-glycan in mAb formats using G4S linkers, as reported in previous publications (Haberger et al. Spahr et al., 2014, MAbs, 6(4):904-914; Spencer et al, 2013, J. Pharm.
- nCE-MS is suitable for the analysis of new formats and can reveal PTMs unique to common mAbs such as O-glycosylation.
- nCE-MS method provides high resolution separation and high sensitivity detection, with excellent system robustness.
- the electropherograms provided by nCE-MS analysis were similar to the chromatograms from SCX and the electropherograms from iCIEF. Therefore, this method can be used for peak identification in SCX and iCIEF studies.
- Antibodies with close pl values can be separated well.
- Co-migrated antibodies were identified individually based on simplified native mass spectra. Increased levels of acidic variants and Fab fragments resulting from incubation under stressed conditions were localized within the F(ab’)2 and Fc domains by subunit analysis.
- nCE-MS analysis can be applied to characterize new modalities including mAbs with or without Fab arms and to detect PTMs such as O-glycosylation.
- PTMs such as O-glycosylation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention pertains to methods for characterizing proteins in a sample using native capillary electrophoresis-mass spectrometry. The present invention pertains to methods for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample, detecting and/or discriminating between antibodies in an antibody mixture, and characterizing monospecific antibody side products in a bispecific antibody sample.
Description
NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY
CROSS-REFERENCE TO RELATED APPLICATIONS
[001] This application claims priority of U.S. continuation-in-part Patent Application No. 17/870,368, filed on July 21, 2022 and is hereby incorporated by reference in its entirety.
REFERENCE TO A SEQUENCE LISTING
[002] The instant application contains a Sequence Listing which has been filed electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on October 14, 2022, is named 070816-01839_SL.xml and is 2.27 bytes in size bytes.
FIELD OF THE INVENTION
[003] The present invention pertains to biopharmaceuticals, and relates to the use of capillary electrophoresis and mass spectral analysis to characterize size and charge variants of therapeutic antibodies.
BACKGROUND
[004] Therapeutic antibodies are a significant class of biotherapeutic products, and they have achieved outstanding success in treating many life-threatening and chronic diseases. However, in certain circumstances therapeutic antibodies, such as monoclonal antibodies (mAbs), are heterogeneous molecules produced in mammalian cells with many product variants, including variants resulting from post-translational modifications (PTMs). Variants produced via PTMs can occur throughout the lifespan of a mAb during production, purification, storage, and postadministration. These variants or product-related modifications are also referred to as product quality attributes (PQAs). Controlling PQAs within predefined acceptance criteria is vital to the biopharmaceutical industry because it ensures consistent product quality and reduces potential impacts on drug safety and efficacy.
[005] Each individual monoclonal antibody may therefore present a unique profile, a characteristic which needs to be taken into consideration during the evaluation of these products both during development and manufacturing of final product. A Food and Drug Administration
guidance for industry recommends that sponsors should evaluate susceptibilities of therapeutic proteins to modifications within the in vivo milieu (see, Guidance for Industry, Immunogenicity Assessment for Therapeutic Protein Products. 2014). As a result, in vitro and/or in vivo behavior of many PQAs, including deamidation (see, for example, Huang et al., Analytical chemistry 2005; 77:1432-9; Ouellette et al., mAbs 2013; 5:432-44; Yin et al., Pharmaceutical research 2013; 30:167-78; Li et al., mAbs 2016:0; Li et al., mAbs 2016:0), oxidation (see, for example, Yin et al., Pharmaceutical research 2013; 30: 167-78; Li et al., mAbs 2016:0; Li et al., mAbs 2016:0), glycation (see, for example, Goetze et al., Glycobiology 2012; 22:221-34), glycosylation (see, for example, Li et al., mAbs 2016:0; Li et al., mAbs 2016:0; Goetze et al., Glycobiology 2011; 21 :949-59; Alessandri et al., mAbs 2012; 4:509-20), disulfides (see, for example, Li Yet al., mAbs 2016:0; Liu et al., The Journal of biological chemistry 2008;
283:29266-72), N-terminal pyroglutamate (see, for example, Yin et al., Pharmaceutical research 2013; 30:167-78; Li et al., mAbs 2016:0; Li et al., mAbs 2016:0; Liu et al., The Journal of biological chemistry 2011; 286: 11211-7), and C-terminal lysine removal (see, for example, Li et al., mAbs 2016:0; Cai et al., Biotechnology and bioengineering 2011; 108:404-12) have been investigated in animal or human samples. Accordingly, additional methods of monitoring mAb preparations are needed.
SUMMARY OF THE INVENTION
[006] A method has been developed for analysis of protein variants, for example size and charge variants of a therapeutic antibody. The method comprises the use of native microfluidic capillary electrophoresis connected in line with mass spectrometry to separate, identify and/or quantify polypeptides in a sample. The method may be used, for example, to characterize post- translational modifications (PTMs) of an antibody, to detect monospecific mAb impurities (referred as either HC/HC or HC*/HC*) in a bispecific antibody (bsAb) sample, and to characterize alternative antibody formats such as “N-l,” which is a one arm antibody, and “N+l” antibodies, where an additional Fab arm was connected to the heavy chain.
[007] In one aspect, the present invention provides a method for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample, in which the method includes: contacting a sample comprising one or more antibodies of interest with a protease to digest the sample into antibody fragments; separating antibody fragments by molecular weight and/or charge in one or more capillaries using capillary
electrophoresis; eluting separated antibody fragments from the one or more capillaries; and determining the mass of the eluted antibody fragments by mass spec analysis, thereby detecting and/or discriminating between post-translational modification variants of the antibody of interest.
[008] In various embodiments of the method, the post-translational modification comprises one or more of deamidation, oxidation, glycation, disulfide formation, N-terminal pyroglutamate formation, C-terminal lysine removal, high mannose glycosylation, and O-glycosylation.
[009] In various embodiments of the method, the protease comprises IdeS.
[0010] In various embodiments of the method, the antibody fragments comprise one or more of an F(ab’)2 or Fc antibody subunit.
[0011] In various embodiments of the method, the antibody of interest is a mAb.
[0012] In various embodiments of the method, the antibody fragments are separated by charge and the method is a method of detecting and/or discriminating between charge variants of the antibody of interest.
[0013] In various embodiments of the method, the antibody fragments are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of the antibody of interest.
[0014] In some embodiments, the method further includes determining a relative or absolute amount of the post-translational modification variants of an antibody of interest in a sample.
[0015] In various embodiments of the method, the antibody of interest comprises a bispecific antibody.
[0016] In various embodiments of the method, the sample includes an internal standard.
[0017] In various embodiments of the method, the one or more capillaries comprise a separation matrix.
[0018] In various embodiments of the method, the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
[0019] In various embodiments of the method, eluting separated antibody fragments from the one or more capillaries further comprises separating the antibody fragments into one or more fractions.
[0020] In some embodiments, the method further includes identifying the antibody fragments.
[0021] In some embodiments, the method further includes identifying the post-translational modification present on the antibody fragments.
[0022] In various embodiments of the method, the monoclonal antibody of interest is of isotype IgGl, IgG2, IgG3, IgG4, or mixed isotype.
[0023] In some embodiments, the method further includes post-translational modification profiling of the antibody of interest.
[0024] In some embodiments, the method further includes post-translational modification mapping of post-translational modification hotspots by reduced peptide mapping LC-MS/MS analysis.
[0025] In various embodiments of the method, the sample comprises a mixture of antibodies of interest.
[0026] In various embodiments of the method, the monoclonal antibody of interest is an antibody drug conjugate.
[0027] This disclosure provides a further method for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample. In some exemplary embodiments, the method comprises (a) contacting a sample comprising one or more antibodies of interest with a protease to digest the sample into antibody fragments; (b) separating antibody fragments by molecular weight and/or charge in one or more capillaries using capillary electrophoresis; (c) eluting separated antibody fragments from the one or more capillaries; and (d) determining the mass of the eluted antibody fragments by mass spectrometry analysis, thereby detecting and/or discriminating between post-translational modification variants of the antibody of interest, wherein said one or more antibodies of interest are maintained in native conditions, and wherein said capillary electrophoresis is in an integrated microfluidic platform.
[0028] In one aspect, the post-translational modification comprises one or more of deamidation, oxidation, glycation, disulfide formation, N-terminal pyroglutamate formation, C- terminal lysine removal, high mannose glycosylation, and O-glycosylation.
[0029] In one aspect, the protease comprises IdeS.
[0030] In one aspect, the antibody fragments comprise one or more of an F(ab’)2 or Fc antibody subunit.
[0031] In one aspect, the antibody of interest is a monoclonal antibody.
[0032] In one aspect, the antibody fragments are separated by charge and the method is a method of detecting and/or discriminating between charge variants of the antibody of interest.
[0033] In one aspect, the antibody fragments are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of the antibody of interest.
[0034] In one aspect, the method further comprises determining a relative or absolute amount of the post-translational modification variants of an antibody of interest in a sample.
[0035] In one aspect, the antibody of interest comprises a bispecific antibody.
[0036] In one aspect, the sample includes an internal standard.
[0037] In one aspect, the one or more capillaries comprise a separation matrix. In a specific aspect, said separating comprises a sieving matrix configured to separate proteins by molecular weight.
[0038] In one aspect, eluting separated antibody fragments from said one or more capillaries further comprises separating the antibody fragments into one or more fractions.
[0039] In one aspect, the method further comprises identifying the antibody fragments.
[0040] In one aspect, the method further comprises identifying the post-translational modification present on the antibody fragments.
[0041] In one aspect, the antibody of interest is of isotype IgGl, IgG2, IgG3, IgG4, or mixed isotype.
[0042] In one aspect, the method further comprises post-translational modification profiling of the antibody of interest.
[0043] In one aspect, the method further comprises post-translational modification mapping of post-translational modification hotspots by reduced peptide mapping LC-MS/MS analysis.
[0044] In one aspect, the sample comprises a mixture of antibodies of interest.
[0045] In one aspect, the antibody of interest is an antibody drug conjugate. In another aspect, the antibody of interest is a “N-l” antibody or a “N+l” antibody.
[0046] In one aspect, an injection volume in the one or more capillaries is between about 1 nL
and about 10 nL. Tn a specific aspect, an injection volume in the one or more capillaries is about 1 nL.
[0047] This disclosure provides a further method for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample. In some exemplary embodiments, the method comprises (a) contacting a sample comprising one or more antibodies of interest with an IdeS protease to digest the sample into antibody fragments, wherein the protease to sample ratio is about 1.25 units of protease to about 1 pg sample; (b) separating antibody fragments by molecular weight and/or charge in one or more capillaries comprising a sieving matrix using capillary electrophoresis; (c) eluting separated antibody fragments from the one or more capillaries; and (d) determining the mass of the eluted antibody fragments by mass spectrometry analysis, thereby detecting and/or discriminating between post- translational modification variants of the antibody of interest, wherein said antibody of interest is maintained in native conditions, and wherein said capillary electrophoresis is in an integrated microfluidic platform.
[0048] This disclosure also provides a method for characterizing a monospecific antibody in a mixture of a bispecific antibody and its monospecific antibody side products. In some exemplary embodiments, the method comprises (a) separating a mixture of a bispecific antibody and its monospecific antibody side products by molecular weight and/or charge in one or more capillaries using capillary electrophoresis; (b) eluting said separated antibody and antibody side products from said one or more capillaries; and (c) determining the mass of said eluted antibody and antibody side products by mass spectrometry, thereby characterizing said monospecific antibody, wherein said monospecific antibody is maintained in native conditions, and wherein said capillary electrophoresis is in an integrated microfluidic platform.
[0049] In one aspect, the method further comprises determining a relative or absolute amount of the monospecific antibody in said mixture.
[0050] In one aspect, the mixture includes an internal standard.
[0051] In one aspect, the one or more capillaries comprise a separation matrix. In a specific aspect, the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
[0052] In one aspect, the monospecific antibody is of isotype IgGl, IgG2, IgG3, IgG4, or
mixed isotype.
[0053] In one aspect, the method further comprises characterizing a second monospecific antibody in the mixture.
[0054] In one aspect, an injection volume in the one or more capillaries is between about 1 nL and about 10 nL. In a specific aspect, an injection volume in the one or more capillaries is about 1 nL.
[0055] In various embodiments, any of the features or components of embodiments discussed above or herein may be combined, and such combinations are encompassed within the scope of the present disclosure. Any specific value discussed above or herein may be combined with another related value discussed above or herein to recite a range with the values representing the upper and lower ends of the range, and such ranges are encompassed within the scope of the present disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0056] FIG. 1 illustrates an exemplary work flow for the separation and detection of post- translational modified antibody fragments by capillary electrophoresis and mass spectral analysis, according to an exemplary embodiment.
[0057] FIG. 2A shows electropherograms evaluating the sensitivity of ZipChip nCE-MS for NISTmAb (IgGl), according to an exemplary embodiment.
[0058] FIG. 2B shows electropherograms evaluating the sensitivity of ZipChip nCE-MS for mAbl (IgGl), according to an exemplary embodiment.
[0059] FIG. 2C shows electropherograms evaluating the sensitivity of ZipChip nCE-MS for mAb2 (IgG4), according to an exemplary embodiment.
[0060] FIG. 2D shows electropherograms evaluating the sensitivity of ZipChip nCE-MS for bsAbl (IgG4), according to an exemplary embodiment.
[0061] FIG. 3 shows mass spectra at the limit of detection (LOD) for NISTmAb, mAbl, mAb2, and bsAbl, according to an exemplary embodiment.
[0062] FIG. 4A shows sensitivity of ZipChip nCE-MS for IgGl, according to an exemplary embodiment.
[0063] FIG. 4B shows sensitivity of ZipChip nCE-MS for IgG4, according to an exemplary
embodiment.
[0064] FIG. 4C shows a carryover test of ZipChip nCE-MS, according to an exemplary embodiment.
[0065] FIG. 5A shows a charge variant profde of deglycosylated NISTmAb, including two basic variants and two acidic variants, according to an exemplary embodiment.
[0066] FIG. 5B shows a mass spectrum of the acidic 2 variant of NISTmAb, demonstrating Fab glycosylation, according to an exemplary embodiment.
[0067] FIG. 5C shows a zoom-in view of a deglycosylated NISTmAb electropherogram, showing three truncated forms, according to an exemplary embodiment.
[0068] FIG. 5D shows mass spectra of three NISTmAb truncation forms cleaved at (i) Cys223/Asp224, (ii) Lys225/Thr226, and (iii) His227/Thr228, according to an exemplary embodiment.
[0069] FIG. 6 shows the charge variant separation of intact NISTmAb and SEQ ID NO: 1, according to an exemplary embodiment.
[0070] FIG. 7A shows an electropherogram of charge variant analysis of antibody F(ab’)2 and Fc subunits for IdeS treated control and stressed NISTmAb, according to an exemplary embodiment.
[0071] FIG. 7B shows an electropherogram of charge variant analysis of antibody F(ab’)2 subunits for IdeS treated control and stressed NISTmAb, according to an exemplary embodiment.
[0072] FIG. 7C shows an electropherogram of charge variant analysis of antibody Fc subunits for IdeS treated control and stressed NISTmAb, according to an exemplary embodiment.
[0073] FIG. 8A shows a separation of three IgGl mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
[0074] FIG. 8B shows a separation of five bispecific IgG4 mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
[0075] FIG. 8C shows a separation of ten mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
[0076] FIG. 8D shows an identification of co-migrated mAbs using ZipChip nCE-MS,
according to an exemplary embodiment.
[0077] FIG. 8E shows an identification of co-migrated mAbs using ZipChip nCE-MS, according to an exemplary embodiment.
[0078] FIG. 9 shows electropherograms for five lots of formulated antibodies manufactured from two different processes, according to an exemplary embodiment.
[0079] FIG. 10 shows mass spectra of main species and basic variant 1 for five lots of mAb3 manufactured with two different processes, according to an exemplary embodiment.
[0080] FIG. 11A shows charge variant separation by SCX-UV, according to an exemplary embodiment.
[0081] FIG. 1 IB shows charge variant separation by ZipChip nCE-MS, according to an exemplary embodiment.
[0082] FIG. 12A shows charge variant separation by iCIEF, according to an exemplary embodiment.
[0083] FIG. 12B shows charge variant separation by ZipChip nCE-MS, according to an exemplary embodiment.
[0084] FIG. 13A shows an electropherogram of bsAbl with 20 ng injection by ZipChip nCE- MS, according to an exemplary embodiment.
[0085] FIG. 13B shows a lOx zoom-in of an electropherogram of bsAbl with 20 ng injection by ZipChip nCE-MS, according to an exemplary embodiment.
[0086] FIG. 13C shows HC*/HC* monospecific mAb impurities at spike-in levels of 1 :500 and 1 :100 in bsAbl by ZipChip nCE-MS, according to an exemplary embodiment.
[0087] FIG. 13D shows a zoom-in view of HC*/HC* monospecific mAb impurities at spike-in levels of 1 :500 and 1 : 100 in bsAbl by ZipChip nCE-MS, according to an exemplary embodiment.
[0088] FIG. 14 shows mass spectra for HC/HC in a bsAbl sample, HC/HC standard, and half mAb by ZipChip nCE-MS, according to an exemplary embodiment.
[0089] FIG. 1 shows mass spectra of HC*/HC* at 0.2% and 1% using ZipChip nCE-MS, according to an exemplary embodiment.
[0090] FIG. 16A shows an electropherogram of an “N-1” format antibody using ZipChip nCE- MS, according to exemplary embodiment.
[0091] FIG. 16B shows an electropherogram of an “N+l” format antibody using ZipChip nCE-MS, according to an exemplary embodiment.
[0092] FIG. 17 shows identification of O-glycosylation (Xyl+Gal+Gal+GlcA) in acidic variant 1 of mAb7 using ZipChip nCE-MS, according to an exemplary embodiment.
DETAILED DESCRIPTION OF THE INVENTION
[0093] Before the present invention is described, it is to be understood that this invention is not limited to particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims. Any embodiments or features of embodiments can be combined with one another, and such combinations are expressly encompassed within the scope of the present invention.
[0094] Unless described otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing, particular methods and materials are now described. All publications mentioned are hereby incorporated by reference.
[0095] The term “a” should be understood to mean “at least one”; and the terms “about” and “approximately” should be understood to permit standard variation as would be understood by those of ordinary skill in the art; and where ranges are provided, endpoints are included.
[0096] Abbreviations Used Herein
[0097] mAb: Monoclonal antibody
[0098] biAb/bsAb: Bispecific antibody
[0099] CQA: Critical quality attributes
[00100] CE: Capillary Electrophoresis
[00101] PTM: Post-Translational Modification
[00102] IEC: Ion Exchange Chromatography
[00103] UV: Ultra Violet
[00104] QC: Quality Control
[00105] MS: Mass Spectrometry
[00106] ADC: Antibody Drug Conjugate
[00107] The term "antibody", as used herein, is intended to refer to immunoglobulin molecules included of four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds (/.<?., "full antibody molecules"), as well as multimers thereof (e.g. IgM) or antigen-binding fragments thereof. Each heavy chain is included of a heavy chain variable region (“HCVR” or “VH”) and a heavy chain constant region (included of domains CHI, CH2 and CH3). In various embodiments, the heavy chain may be an IgG isotype. In some cases, the heavy chain is selected from IgGl, IgG2, IgG3 or IgG4. In some embodiments, the heavy chain is of isotype IgGl or IgG4, optionally including a chimeric hinge region of isotype IgGl/IgG2 or IgG4/IgG2. Each light chain is included of a light chain variable region (“LCVR or “VL”) and a light chain constant region (CL). The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyterminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The term “antibody” includes reference to both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass. The term “antibody” includes antibody molecules prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell transfected to express the antibody. For a review on antibody structure, see Lefranc et al., JMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains, 27(1) Dev. Comp. Immunol. 55-77 (2003); and M. Potter, Structural correlates of immunoglobulin diversity, 2(1) Surv. Immunol. Res. 27-42 (1983).
[00108] The term antibody also encompasses a “bispecific antibody”, which includes a heterotetrameric immunoglobulin that can bind to more than one different epitope. One half of the bispecific antibody, which includes a single heavy chain and a single light chain and six CDRs, binds to one antigen or epitope, and the other half of the antibody binds to a different antigen or epitope. In some cases, the bispecific antibody can bind the same antigen, but at different epitopes or non-overlapping epitopes. In some cases, both halves of the bispecific
antibody have identical light chains while retaining dual specificity. Bispecific antibodies are described generally in U.S. Patent App. Pub. No. 2010/0331527 (Dec. 30, 2010).
[00109] Co-expression of two unique heavy chains (HC and HC*) and one common light chain will minimize a number of side products to two monospecific mAb impurities, which may need to be subsequently detected and removed during purification. The two impurities may be referred to as HC/HC and HC*/HC* respectively. In some exemplary embodiments, the CH3 domain of one heavy chain contains amino acid substitutions that prevent binding to protein A, for example H95R and Y96F substitutions. In some exemplary embodiments, the method of the present invention can be used to detect, identify, quantify, and/or remove monospecific mAb impurities in a sample comprising a bispecific antibody.
[00110] The term antibody also encompasses alternative antibody formats including, for example, “N-l”, which is a one arm antibody, and “N+l”, where an additional Fab arm is connected using, for example, a G4S linker. The method of the present invention can also be used in the analysis of, for example, antibody subunits, antibody fusion proteins, single chain variable fragments (scFvs), diabodies, triabodies, and other antigen-binding proteins or any protein of interest.
[00111] The term “anti gen -binding portion” of an antibody (or “antibody fragment”), refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al. (1989) Nature 241:544-546), which consists of a VH domain, (vi) an isolated CDR, and (vii) an scFv, which consists of the two domains of the Fv fragment, VL and VH, joined by a synthetic linker to form a single protein chain in which the VL and VH regions pair to form monovalent molecules. Other forms of single chain antibodies, such as diabodies are also encompassed under the term “antibody” (see e.g., Holliger et at.
(1993) 90 PNAS U.S.A. 6444-6448; and Poljak et at. (1994) 2 Structure 1 121 -1 123).
[00112] Moreover, antibodies and antigen-binding fragments thereof can be obtained using standard recombinant DNA techniques commonly known in the art (see Sambrook et al., 1989).
[00113] The term "human antibody", is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human mAbs of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include mAbs in which CDR sequences derived from the germline of another mammalian species (e.g., mouse), have been grafted onto human FR sequences. The term includes antibodies recombinantly produced in a non-human mammal, or in cells of a non-human mammal. The term is not intended to include antibodies isolated from or generated in a human subject.
[00114] The term “ADC” or “antibody-drug conjugate” refers to an antibody or antigen-binding fragment thereof conjugated to a therapeutic moiety such as a cytotoxic agent, a chemotherapeutic drug, immunosuppressant or a radioisotope. Cytotoxic agents include any agent that is detrimental to the growth, viability or propagation of cells. Examples of suitable cytotoxic agents and chemotherapeutic agents for forming ADCs are known in the art.
[00115] The term “sample,” as used herein, refers to a mixture of molecules that includes at least one polypeptide of interest, such as a monoclonal antibody or a bispecific antibody or fragment thereof, that is subjected to manipulation in accordance with the methods of the invention, including, for example, separating, analyzing, extracting, concentrating or profding.
[00116] The terms “analysis” or “analyzing,” as used herein, are used interchangeably and refer to any of the various methods of separating, detecting, isolating, purifying, solubilizing, detecting and/or characterizing molecules of interest (e.g., polypeptides, such as antibodies) and contaminants in antibody preparations. Examples include, but are not limited to, electrophoresis, mass spectrometry, e.g. tandem mass spectrometry, ultraviolet detection, and combinations thereof.
[00117] “Chromatography,” as used herein, refers to the process of separating a mixture, for example a mixture containing peptides, proteins, polypeptides and/or antibodies, such as monoclonal antibodies. It involves passing a mixture through a stationary phase, which separates molecules of interest from other molecules in the mixture and allows one or more molecules of interest to be isolated.
[00118] The term "isolated,” as used herein, refers to a biological component (such as an antibody, for example a monoclonal antibody) that has been substantially separated, produced apart from, or purified away from other biological components in the cell of the organism in which the component naturally occurs or is transgenically expressed, that is, other chromosomal and extrachromosomal DNA and RNA, proteins, lipids, and metabolites. Nucleic acids, peptides, proteins, lipids and metabolites which have been "isolated" thus include nucleic acids, peptides, proteins, lipids, and metabolites purified by standard or non-standard purification methods. The term also embraces nucleic acids, peptides, proteins, lipids, and metabolites prepared by recombinant expression in a host cell as well as chemically synthesized peptides, lipids, metabolites, and nucleic acids.
[00119] The terms “peptide,” “protein” and “polypeptide” refer, interchangeably, to a polymer of amino acids and/or amino acid analogs that are joined by peptide bonds or peptide bond mimetics. The twenty naturally-occurring amino acids and their single-letter and three-letter designations are as follows: Alanine A Ala; Cysteine C Cys; Aspartic Acid D Asp; Glutamic acid E Glu; Phenylalanine F Phe; Glycine G Gly; Histidine H His; Isoleucine I He; Lysine K Lys; Leucine L Leu; Methionine M Met; Asparagine N Asn; Proline P Pro; Glutamine Q Gin; Arginine R Arg; Serine S Ser; Threonine T Thr; Valine V Vai; Tryptophan W Trp; and Tyrosine Y Tyr. In one embodiment, a peptide is an antibody or fragment or part thereof, for example, any of the fragments or antibody chains listed above. In some embodiments, the peptide may be post-translationally modified. As used herein, the terms “protein of interest” and/or “target protein of interest” refer to any protein to be separated and/or detected with the methods provided herein. Suitable proteins of interest include antibodies, for example monoclonal antibodies, and fragments thereof.
[00120] ‘ ‘Detect” and “detection” have their standard meaning, and are intended to encompass detection including the presence or absence, measurement, and/or characterization of a protein of interest, such as a mAb or fragment thereof.
[00121] As used herein, the terms “standard” and/or “internal standard” refer to a well- characterized substance of known amount and/or identity (e.g., known molecular weight, electrophoretic mobility profile) that can be added to a sample and both the standard and the molecules in the sample, on the basis of molecular weight or isoelectric point by
electrophoresis). A comparison of the standard then provides a quantitative or semi -quantitative measure of the amount of analyte, such as mAb or fragments thereof present in the sample.
[00122] “Contacting,” as used herein, includes bringing together at least two substances in solution or solid phase, for example contacting a sample with an enzyme, such as a protease.
[00123] The term "corresponding" is a relative term indicating similarity in position, purpose or structure, and may include peptides of identical structure but for the presence or absence of a post-translational modification. In some embodiments, mass spectral signals in a mass spectrum that are due to corresponding peptides of identical structure but for the presence or absence of a post-translational modification are "corresponding" mass spectral signals. A mass spectral signal due to a particular peptide is also referred to as a signal corresponding to the peptide. In certain embodiments, a particular peptide sequence or set of amino acids can be assigned to a corresponding peptide mass.
[00124] The terms “fragment peptide” or “peptide fragment,” as used herein, refer to a peptide that is derived from the full-length polypeptide, such as a protein and/or monoclonal antibody, through processes including fragmentation, enzymatic proteolysis, or chemical hydrolysis. Such proteolytic peptides include peptides produced by treatment of a protein with one or more proteases, such as IdeS protease. A fragment peptide, or peptide fragment, can be a digested peptide.
[00125] ‘ ‘Mass spectrometry” refers to a method in which a sample is analyzed by generating gas phase ions from the sample, which are then separated according to their mass-to-charge ratio (m/z) and detected. Methods of generating gas phase ions from a sample include electrospray ionization (ESI), matrix-assisted laser desorption-ionization (MALDT), surface-enhanced laser desorption-ionization (SELDI), chemical ionization, and electron-impact ionization (El). Separation of ions according to their m/z ratio can be accomplished with any type of mass analyzer, including quadrupole mass analyzers (Q), time-of-flight (TOF) mass analyzers, magnetic sector mass analyzers, 3D and linear ion traps (IT), orbitrap mass analyzer, Fourier- transform ion cyclotron resonance (FT-ICR) analyzers, and combinations thereof (for example, a quadrupole-time-of- flight analyzer, or Q-TOF analyzer). Prior to separation, the sample may be subjected to one or more dimensions of chromatographic separation, for example, one or more dimensions of liquid or size exclusion chromatography.
[00126] Tandem mass spectrometry or MS/MS is a technique to break down selected ions
(precursor ions) into fragments (product ions) The fragments then reveal aspects of the chemical structure of the precursor ion. In tandem mass spectrometry, once samples are ionized (for example by ESI, MALDI, El, etc.) to generate a mixture of ions, precursor ions, for example peptides from a digest of a specific mass-to-charge ratio ( /z) are selected (MSI) and then fragmented (MS2) to generate product ions for detection. Typical tandem MS instruments include QqQ, QTOF, and hybrid ion trap/FTMS, etc. One example of an application of tandem mass spectrometry is protein identification. The first mass analyzer isolates ions of a particular m/z value that represent a single species of peptide among many introduced into and then emerging from the ion source. Those ions are then accelerated into a collision cell containing an inert gas such as argon to induce ion fragmentation. This process is designated collisionally induced dissociation (CID) or collisionally activated dissociation (CAD). The m/z values of fragment ions are then measured in a 2nd mass analyzer to obtain amino acid sequence information.
[00127] References to a mass of an amino acid mean the monoisotopic mass or average mass of an amino acid at a given isotopic abundance, such as a natural abundance. In some examples, the mass of an amino acid can be skewed, for example, by labeling an amino acid with an isotope. Some degree of variability around the average mass of an amino acid is expected for individual single amino acids based on the exact isotopic composition of the amino acid. The masses, including monoisotopic and average masses for amino acids are easily obtainable by one of ordinary skill the art.
[00128] Similarly, references to a mass of a peptide means the monoisotopic mass or average mass of a peptide at a given isotopic abundance, such as a natural abundance. In some examples, the mass of a peptide can be skewed, for example, by labeling one or more amino acids in the peptide with an isotope. Some degree of variability around the average mass of a peptide is expected for individual single peptides based on the exact isotopic composition of the peptide. The mass of a particular peptide can be determined by one of ordinary skill the art.
[00129] In some exemplary embodiments, CE, MS, and CE-MS can be performed under native conditions (nCE-MS). As used herein, the term “native conditions” can include performing capillary electrophoresis and/or mass spectrometry under conditions that preserve non-covalent interactions in an analyte, in contrast to, for example, reducing and/or denaturing conditions. Native capillary electrophoresis and/or mass spectrometry is an approach to study intact
biomolecular structure in the native or near-native state. The term “native” refers to the biological status of the analyte in solution prior to subjecting to separation and/or ionization. Several parameters, such as pH and ionic strength, of the solution containing the biological analytes can be controlled to maintain the native folded state of the biological analytes in solution.
[00130] General Description
[00131] Therapeutic antibodies are a major class of biopharmaceuticals that have been developed as treatments for a variety of therapeutic areas including infectious diseases (Sparrow etal., 2017, Bull. World Health Organ., 95(3):235-237), inflammation and immunology (Chan et al., 2010, Nat. Rev. Immunol., 10(50):301-316), oncology (Scott et al., 2012, Nat. Rev. Cancer., 12(4):278-287), hematology (Cuesta-Mateos et al., 2017, Front. Immunol., 8: 1936), ophthalmology (Rodrigues etal., 2009, Prog. Retin. Eye Res.), 28(2): 117-144, and rare diseases (Tambuyzer et al., 2020, Nat. Rev. Drug Discov., 19(2): 93 - 111). The advantages of therapeutic antibodies include the high specificity and binding affinity to their molecular targets, and generally low immunotoxicity and mild adverse effects (Rodrigues etal.,- Lu et al., 2020, J. Biomed. Sci., 27(1): 1). Monoclonal antibodies (mAbs) including immunoglobulin G (IgG) subclasses, such as IgGl and IgG4, have attracted the most attention, because of their simpler structures and longer half-lives than those of other subclasses. The structure of these antibodies consists of two identical heavy chains and light chains, with intrachain and interchain disulfide bond linkage (Chiu et al., 2019, Antibodies (Basel), 8:55). Additionally, bispecific antibodies (bsAbs), in which the two heavy chains and light chains may be different, and other IgG-based molecules in alternative formats, such as those with addition and removal of the antigen-binding fragment (Fab) arm, have also been created to achieve advantageous properties such as the ability to interact with multiple therapeutic targets (Labrijn et al., 2019, Nat. Rev. Drug Discov., 18(8):585-608; Seung et aL, 2022, Nature, 603(7900):328-334; Spiess et al., 2015, Mol.
Immunol., 67(95-106)). In cancer treatment, bsAbs can achieve high target specificity through one paratope and recruitment of tumor killing agents through the other paratope (Runcie et al., 2018, Afo/. Med., 24(l):50).
[00132] Characterization of antibody variants is important in order to identify their potential impact on safety, potency, and stability of a potential therapeutic antibody. For example, to be considered for approval by regulatory agencies, extensive characterization of the molecule must
be performed. Tn drug products comprising mixtures of antibodies, characterization of the absolute or relative amounts of each antibody must be determined. Because aggregates and fragments may potentially affect immunogenicity and potency, their levels are typically monitored during lot release, stability, and characterization. Furthermore, primary degradation pathways for the molecule and product related impurities and variants are determined.
[00133] Characterization of these therapeutic antibodies and their derivatives has become more challenging, owing to the increasing complexity of these biomolecules and their heterogeneity. For example, post-translational modifications (PTMs) commonly occur on therapeutic antibodies in bioreactors during production (Wurm, 2004, Nat. Biotechnol., 22(11): 1393-1398). These modifications include glycosylation, asparagine deamidation, aspartic acid isomerization and cyclization, methionine and tryptophan oxidation, and lysine glycation, among others (Liu et al., 2008, J. Pharm. Set., 97(7): 2426-2447). As amino acid residues are modified, the electrostatic environment surrounding the amino acids changes, thereby resulting in a net charge difference in the molecule and the formation of charge variants (Du etal., 2012, MAbs, 4(5):578-585). For instance, lysine glycation adds a neutrally charged monosaccharide to a positively charged and basic lysine residue, thus resulting in an acidic variant. Methionine oxidation changes a methionine residue to a methionine sulfone, thus resulting in a basic variant. Moreover, cellular processing also causes the formation of charge variants, including incomplete cleavage of C- terminal lysine, and incomplete cyclization of the N-terminal glutamine residue. Mass spectrometry (MS) has been extensively used to study PTMs at the peptide, subunit, and intact levels (Zhang et al., 2014, EEBS Lett., 588(2):308-317). Peptide mapping, wherein therapeutic antibodies are digested with enzymes, can be used to monitor multiple PTMs simultaneously and have been widely adopted (Rogstad et al., 2017, J. Am. Soc. Mass Spectrom., 28(5):786-794). Additionally, intact mass analysis of therapeutic antibodies at both the subunit and intact levels has also been performed (Jin etal., 2019, MAbs, 11(1): 106-115).
[00134] Charge variant analysis is critical for understanding the structure of biotherapeutics during drug development and product release (Du et al.). The charge variant profile can be characterized by several analytical techniques, including imaged capillary isoelectric focusing (iCIEF) and cation exchange chromatography (CEX), to enable relative quantification of charge variants. The iCIEF technique separates charge species according to the isoelectric point (pl) (Salas-Solano etal., 2011, Chromatographia, 73(11): 1137-1144). CEX is a chromatographic
technique that separates species according to surface charge, and strong cation exchange (SCX) is a common method used for therapeutic antibody analysis (Fekete et al., 2015, J. Pharm. Biomed Anal., 113:43-55). For iCIEF, electropherograms are generated according to optical detection, and thus the identity of the separated charge variants is not determined. Although several iCIEF-MS platforms have been demonstrated to provide pl based separation and charge variant identification (Mack et al., 2019, Electrophoresis, 40(23-24):3084-3091; He et al., 2022, Electrophoresis), these platforms remain under development and are not widely adopted. Recent advances have enabled direct coupling of CEX to MS through use of MS-compatible salt; however, higher resolution separation is normally achieved with MS-incompatible buffer rather than MS-compatible buffer (Yan et al., 2018, Anal. Chem., 90(21): 13013-13020; Ma etal., 2020, MAbs, 12(1):1763762).
[00135] ZipChip is an integrated microfluidic capillary electrophoresis (CE) system that can be directly coupled with the MS interface, and has been used to analyze small molecules in media, monosaccharides and oligosaccharides (Ribeiro da Silva et al., 2021, J. Chromatogr. A, 1651 :462336; Khatri et al., 2017, Anal. Chem., 89(12):6645-6655); peptides for antibody protein sequence confirmation and proteomic analysis (Khatri etal.; Dykstra et al., 2021, J. Am. Soc. Mass Spectrom., 32(8): 1952-1963; Cao et al., 2021, J. Pharm. Biomed. Anal., 204:114251); and intact proteins including fusion proteins (Deyanova et al. 2021, Electrophoresis, 42(4):460-464), mAbs (Cao et al:, Sun et aL, 2021, Anal. Biochem., 625: 114214; Redman et al, 2015, Anal. Chem., 87(4):2264-2272), and antibody-drug conjugates (Redman et al., 2016, Anal. Chem., 88(4):2220-2226). Due to the low flow nature of CE and high ionization efficiency of nanoelectrospray, this integrated system is able to provide high resolution separation and high sensitivity detection. With the native CE-MS (nCE-MS) method, charge variants are separated on the basis of both protein charge and size under native conditions (Redman et al., 2015).
During separation, the charge variants with more positive charges migrate faster and elute earlier in the native BGE (pH < pl of antibody), whereas variants with fewer positive charges migrate slowly in the separation channel under the electric field. Therefore, in a typical antibody charge separation profile, basic variants elute first, followed by the main species and acid variants. Additionally, the ZipChip interface is compatible with common formulation buffer components containing anionic or nonionic detergents for easy sample preparation.
[00136] Disclosed herein is a highly sensitive, high-resolution microfluidic nCE-MS method for detecting and/or discriminating between variants of an antibody of interest, such as a therapeutic antibody, in a sample by a physical parameter, such as mass and/or charge. The method may be used, for example, for antibody charge variant and impurity analysis, and for the quick identification of antibody charge variants for forced degradation and long-term stability studies. The sensitivity was first evaluated with three types of therapeutic antibodies. Additionally, antibody samples from different manufacturing processes and lots, as well as the antibody cocktail, were analyzed with the nCE-MS method. Comparative analysis of charge variant profiles was performed for the nCE-MS, SCX and iCIEF methods. The high sensitivity of the nCE-MS method enabled detection of fragments with very low abundance in the antibody sample and homospecific mAb impurities in the bsAb sample. Finally, new antibody modalities were evaluated with the nCE-MS method.
[00137] The disclosed methods can be used in QC evaluation of antibody preparations. In embodiments of the method, a sample that includes an antibody of interest is resolved or separated by using capillary electrophoresis, for example on one or more capillaries of a CE- system. In certain embodiments, the sample is resolved or separated by molecular weight and charge. For example, using separation by mass and charge, or m/z ratio, fragments with the same mass but different charges can be resolved. Similarly, using separation by mass and charge, or m/z ratio, fragments with the same charge but different masses can be resolved. In embodiments, the method includes liberating fragments of an antibody of interest, such as a monoclonal antibody (mAb), for example by contacting the sample comprising one or more antibodies of interest with a protease to digest the sample. In an embodiment, the protease is IdeS protease. Once digestion, either partial or full, is conducted, antibody fragments can be separated by molecular weight and/or charge in one or more capillaries using capillary electrophoresis. The separated antibody fragments can be eluted from the one or more capillaries and the mass of the eluted antibody fragments determined by mass spec analysis to detect and/or discriminate between post-translational modification variants of the antibody of interest, for example by detection and/or determination of the PTM profile of the fragments of the antibody of interest. In certain embodiments, the antibody fragments include one or more of an F(ab’)2 or Fc antibody subunit, for example as digested from the intact antibody using a protease, such as the IdeS protease. In certain embodiments, the antibody of interest is a monoclonal antibody, such as a currently used therapeutic antibody or one undergoing
evaluation, including novel monoclonal antibodies. Tn certain embodiments, the monoclonal antibody of interest is part of an antibody drug conjugate (ADC). In certain embodiments, the antibody fragments are separated by charge and the method is a method of detecting and/or discriminating between charge variants of the antibody of interest. In certain embodiments, the antibody fragments are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of the antibody of interest. In certain embodiments, the antibody fragments are separated by charge and molecular weight and the method is a method of detecting and/or discriminating between charge and molecular weight variants of the antibody of interest. In certain embodiments, the method includes determining a relative or absolute amount of the post-translational modification variants of an antibody of interest in a sample, for example from the antibody fragments.
[00138] As noted above, separation of the antibody fragments by mass and charge has the benefit of being able to determine the homogeneity of the antibody fragments, for example, changes in surface charge of the antibody that may not be easily seen in separation by just molecular weight. This separation allows for the determination of the type and level of post- translational modification on the fragments in the sample. The presence of post -translational modifications (PTMs) on a monoclonal antibody (mAb) induces charge heterogeneity (see Table 1) and potentially affects drug stability and biological activity. Therefore, monitoring the PTMs and associated charge variant profiles of mAbs during drug development is important. Disclosed herein is the development of a high-throughput and highly sensitive native microfluidic CE-MS method for the quick identification of mAb charge variants and its application to forced degradation and long-term stability studies. Relative to ion exchange chromatography (IEX) based approaches, high resolution with comparable charge variant profiles can be obtained using the native microfluidic CE-MS method as disclosed herein.
[00139] In certain embodiments, the post-translational modification is one or more of deamidation, oxidation, glycation, disulfide formation, N-terminal pyroglutamate formation, C- terminal lysine removal, high mannose glycosylation, and O-glycosylation.
[00140] In certain embodiments, the sample is resolved or separated within a single capillary. In certain embodiments, the sample is resolved or separated within multiple capillaries, for example in parallel. By way of example with respect to separation by molecular weight, the smaller the fragment of an antibody, the further within a capillary it would be expected to travel over a given period of time. In addition, one would expect differences in the charge of antibody fragments to be subjected to different travel times depending on the charge.
[00141] In embodiments, the sample may contain multiple, such as at least 2, at least 3, at least 4, at least 5 or more sets of antibody fragments from multiple antibodies of interest. In some embodiments, the method further includes determining a relative or absolute amount of the variants of the antibody fragments in a sample, for example by measurement of peak height or area, which corresponds to the amount of antibody fragment in the sample. In some embodiments, the antibody of interest comprises a bispecific monoclonal antibody. In some embodiments, the sample includes one or more internal standards, for example a ladder of molecular weight standards, a ladder of isoelectric point standards, or even a standard used as a baseline or benchmark for determining the amount of an antibody fragments of interest in the sample.
[00142] The ability to discriminate between mAbs in a mAb cocktail of multiple mAbs is becoming increasingly important as these multiple component therapies demonstrate increased efficacy in disease treatment. Thus, improved methods of monitoring how the individual mAbs behave in these systems will become increasingly important in the assessment of the
compatibility and stability of these multi-mAb therapies. To meet this growing need this disclosure provides a method for detecting and/or discriminating between monoclonal antibodies in a mixture of two of more monoclonal antibodies in a sample.
[00143] In embodiments, the method includes separating protein components of a sample with two or more mAbs of interest, such as 2, 3, 4, 5, 6, 7, 8, 9 10 or even more, mAbs of interest, by charge in one or more capillaries using capillary electrophoresis
[00144] In some embodiments, a charge based profile or fingerprint of the antibody of interest can be created, for example of the antibody of interest alone for comparison with a charge based profile or fingerprint of the antibody in the mixture, for example a charge based profile or fingerprint corresponding to the post-translational modification. This comparison can then be used to determine if the antibody of interest changes in the mixture. This profile or fingerprint comparison can be done for any or all of the antibodies of interest in the mixture.
[00145] Samples for use in the disclosed methods can be heterogeneous, containing a variety of components, i.e. different proteins. Alternatively, the sample can be homogenous, containing one component or essentially one component of multiple charge or molecular weight species. Pre-analysis processing may be performed on the sample prior to detecting the antibody of interest, such as a mAb or multiple mAbs. For example, the sample can be subjected to a lysing step, denaturation step, heating step, purification step, precipitation step, immunoprecipitation step, column chromatography step, centrifugation, etc. In some embodiments, the separation of the sample and immobilization may be performed on native substrates. In other embodiments, the sample may be subjected to denaturation, for example, heat and/or contact with a denaturizing agent. Denaturizing agents are known in the art. In some embodiments, the sample may be subjected to non-reducing conditions. In some embodiments, the sample may be subjected to reducing conditions, for example, by contacting the sample with one or more reducing agents. Reducing agents are knowns in the art.
[00146] In embodiments, the capillary may include a separation matrix, which can be added in an automated fashion by the apparatus and/or system. In some embodiments, the sample is loaded onto a stacker matrix prior to separation. The separation matrix, in one embodiment, is a size separation matrix, and has similar or substantially the same properties of a polymeric gel, used in conventional electrophoresis techniques. Capillary electrophoresis in the separation matrix is analogous to separation in a polymeric gel, such as a polyacrylamide gel or an agarose
gel, where molecules are separated on the basis of the size of the molecules in the sample, by providing a porous passageway through which the molecules can travel. The separation matrix permits the separation of molecules by molecular size because larger molecules will travel more slowly through the matrix than smaller molecules. In some embodiments, the one or more capillaries comprise a separation matrix. In some embodiments, the sample containing an antibody of interest is separated or resolved based on molecular weight. In some embodiments, the separation matrix comprises a sieving matrix configured to separate proteins by molecular weight. In some embodiments, protein components of a sample are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of an antibody of interest. In some embodiments, antibody fragments of a sample are separated by molecular weight and the method is a method of detecting and/or discriminating between size variants of a contaminating protein of interest.
[00147] A wide variety of solid phase substrates are known in the art, for example gels, such as polyacrylamide gel. In some embodiments, resolving one or more proteins of interest includes electrophoresis of a sample in a polymeric gel. Electrophoresis in a polymeric gel, such as a polyacrylamide gel or an agarose gel separates molecules on the basis of the molecule's size. A polymeric gel provides a porous passageway through which the molecules can travel. Polymeric gels permit the separation of molecules by molecular size because larger molecules will travel more slowly through the gel than smaller molecules.
[00148] In some embodiments, the sample containing a protein of interest is separated or resolved based on the charge of the components of the sample. In some embodiments, protein components of a sample are separated by charge and the method is a method of detecting and/or discriminating between charge variants of a monoclonal antibody of interest. In some embodiments, fragments of a sample are separated by charge and the method is a method of detecting and/or discriminating between charge variants of an antibody of interest of interest.
[00149] In some embodiments, an internal standard can be a purified form of the antibody of interest itself or fragment thereof, which is generally made distinguishable from the antibody of interest in some way. Methods of obtaining a purified form of the antibody of interest itself or fragment thereof can include, but are not limited to, purification from nature, purification from organisms grown in the laboratory (e.g., via chemical synthesis), and/or the like. The distinguishing characteristic of an internal standard can be any suitable change that can include,
but is not limited to, dye labeling, radiolabeling, or modifying the mobility of the standard during the electrophoretic separation so that it is separated from the antibody of interest. For example, a standard can contain a modification of the antibody of interest itself or fragment thereof that changes the charge, mass, and/or length (e.g., via deletion, fusion, and/or chemical modification) of the standard relative to the antibody of interest itself or fragment thereof. Thus, the antibody of interest itself or fragment thereof and the internal standard can each be labeled with fluorescent dyes that are each detectable at discrete emission wavelengths, thereby allowing the protein of interest and the standard to be independently detectable. In some instances, an internal standard is different from the antibody of interest itself or fragment thereof but behaves in a way similar to or the same as the antibody of interest itself or fragment thereof, enabling relevant comparative measurements.
[00150] As will be appreciated by those of skill in the art, virtually any method of loading the sample in the capillary may be performed. For example, the sample can be loaded into one end of the capillary. In some embodiments, the sample is loaded into one end of the capillary by hydrodynamic flow. For example, in embodiments wherein the fluid path is a capillary, the sample can be loaded into one end of the capillary by hydrodynamic flow, such that the capillary is used as a micropipette. In some embodiments, the sample can be loaded into the capillary by electrophoresis, for example, when the capillary is gel fdled and therefore more resistant to hydrodynamic flow.
[00151] The capillary can include any structure that allows liquid or dissolved molecules to flow. Thus, the capillary can include any structure known in the art, so long as it is compatible with the methods. In some embodiments, the capillary is a bore or channel through which a liquid or dissolved molecule can flow. In some embodiments, the capillary is a passage in a permeable material in which liquids or dissolved molecules can flow.
[00152] The capillary includes any material that allows the detection of the protein of interest within the capillary. The capillary includes any convenient material, such as glass, plastic, silicon, fused silica, gel, or the like. In some embodiments, the method employs a plurality of capillaries. A plurality of capillaries enables multiple samples to be analyzed simultaneously.
[00153] The capillary can vary as to dimensions, width, depth and cross-section, as well as shape, for example being rounded, trapezoidal, rectangular, etc. The capillary can be straight, rounded, serpentine, or the like. As described below, the length of the fluid path depends in part
on factors such as sample size and the extent of sample separation required to resolve the protein of interest.
[00154] In some embodiments, the capillary includes a tube with a bore. In some embodiments, the method employs a plurality of capillaries. Suitable sizes include, but are not limited to, capillaries having internal diameters of about 10 to about 1000 pm, although more typically capillaries having internal diameters of about 25 to about 400 pm can be utilized. Smaller diameter capillaries use relatively low sample loads while the use of relatively large bore capillaries allows relatively high sample loads and can result in improved signal detection.
[00155] The capillaries can have varying lengths. Suitable lengths include, but are not limited to, capillaries of about 1 to 20 cm in length, although somewhat shorter and longer capillaries can be used. In some embodiments, the capillary is about 1, 2, 3, 4, 5, or 6 cm in length. Longer capillaries typically result in better separations and improved resolution of complex mixtures. Longer capillaries can be of particular use in resolving low abundance proteins of interest.
[00156] Generally, the capillaries are composed of fused silica, although plastic capillaries and PYREX (i.e., amorphous glass) can be utilized. As noted above, the capillaries do not need to have a round or tubular shape. Other shapes, so long as they are compatible with the methods described herein, may also be used.
[00157] In some embodiments, the capillary can be a channel. In some embodiments, the method employs a plurality of channels. In some embodiments, the capillary can be a channel in a microfluidic device. Microfluidics employ channels in a substrate to perform a wide variety of operations. The microfluidic devices can include one or a plurality of channels contoured into a surface of a substrate. The microfluidic device can be obtained from a solid inert substrate, and in some embodiments in the form of a chip. The dimensions of the microfluidic device are not critical, but in some embodiments the dimensions are on the order of about 100 pm to about 5 mm thick and approximately about 1 centimeter to about 20 centimeters on a side. Suitable sizes include, but are not limited to, channels having a depth of about 5 pm to about 200 pm, although more typically having a depth of about 20 pm to about 50 pm can be utilized. Smaller channels, such as micro or nanochannels can also be used, so long as they are compatible with the methods.
[00158] The antibody fragments may be obtained from an antibody of interest, such as a monoclonal antibody. The antibody fragments may be prepared by reduction, enzymatic
digestion, denaturation, fragmentation, chemical cleavage or a combination thereof. The methods disclosed herein are applicable to any antibody isotype, such as IgGl, IgG2, IgG3, IgG4, or mixed isotype.
[00159] Reduction is to reduce disulfide bonds into two thiols in a 3-dimensional protein, such as a monoclonal antibody. Reduction can be performed by heat-denaturing, adding a surfactant, or adding a denaturing agent, e.g., guanidine HC1 (6M), in the presence of a reducing agent, e.g. TCEP-HC1. Enzymatic degradation is a digestion of the protein with a protease, e.g., trypsin or Achromobacter protease I (Lys-C). In addition, the glycoprotein can be denatured by heat or chemicals, or a combination thereof. Fragmentation involves cleaving protein portions of a single or multi-subunit protein, such as a monoclonal antibody, with physical, biological or chemical methods. For example, an immunoglobulin degrading enzyme from S. pyogenes (IdeS) is commonly used for antibody subunit fragmentation.
[00160] In various embodiments, an antibody in a sample can be treated and prepared by reduction, enzymatic degradation, denaturation or fragmentation prior to contacting with the hydrophilic enrichment substrate. The methods provide a novel chromatographic method to characterize the post-translational modification of antibodies, e.g., monoclonal antibody (mAb) therapeutics, by means of fragments. In certain embodiments, the samples at any intervening step may be concentrated, desalted or the like.
[00161] In some embodiments, the methods further comprise detecting the post-translationally modified antibody fragments, for example using the UY signal from the peptide portion of the post-translationally modified antibody fragments. This may be done for fractions of a sample and allows the selection of specific fractions for further analysis, for example mass spec (MS) analysis. Thus, in further embodiments, the detection step comprises mass spectrometry or liquid chromatography-mass spectrometry (LC-MS). In applications of mass spectrometry for the analysis of biomolecules, the molecules are transferred from the liquid or solid phases to gas phase and to vacuum phase. Since many biomolecules are both large and fragile (proteins being a prime example), two of the most effective methods for their transfer to the vacuum phase are matrix-assisted laser desorption ionization (MALDI) or electrospray ionization (ESI). Aspects of the use of these methods, and sample preparation requirements, are known to those of ordinary skill in the art. In general, ESI is more sensitive, while MALDI is faster. Significantly, some peptides ionize better in MALDI mode than ESI, and vice versa (Genome Technology, June 220,
p 52). The extraction channel methods and devices of the instant invention are particularly suited to preparing samples for MS analysis, especially biomolecule samples such as post- translationally modified antibody fragments. An important advantage of the invention is that it allows for the preparation of an enriched sample that can be directly analyzed, without the need for intervening process steps, e.g., concentration or desalting.
[00162] ESI is performed by mixing the sample with volatile acid and organic solvent and infusing it through a conductive needle charged with high voltage. The charged droplets that are sprayed (or ejected) from the needle end are directed into the mass spectrometer, and are dried up by heat and vacuum as they fly in. After the drops dry, the remaining charged molecules are directed by electromagnetic lenses into the mass detector and mass analyzed. In one embodiment, the eluted sample is deposited directly from the capillary into an electrospray nozzle, e.g., the capillary functions as the sample loader. In another embodiment, the capillary itself functions as both the extraction device and the electrospray nozzle.
[00163] For MALDI, the analyte molecules (e.g., proteins) are deposited on metal targets and co-crystallized with an organic matrix. The samples are dried and inserted into the mass spectrometer, and typically analyzed via time-of-flight (TOF) detection. In one embodiment, the eluted sample is deposited directly from the capillary onto the metal target, e g , the capillary itself functions as the sample loader. In one embodiment, the extracted analyte is deposited on a MALDI target, a MALDI ionization matrix is added, and the sample is ionized and analyzed, e.g., by TOF detection.
[00164] In some embodiments, other ionization modes are used e.g. ESLMS, turbospray ionization mass spectrometry, nanospray ionization mass spectrometry, thermospray ionization mass spectrometry, sonic spray ionization mass spectrometry, SELDLMS and MALDI-MS. In general, an advantage of these methods is that they allow for the “just-in-time” purification of sample and direct introduction into the ionizing environment. It is important to note that the various ionization and detection modes introduce their own constraints on the nature of the desorption solution used, and it is important that the desorption solution be compatible with both. For example, the sample matrix in many applications must have low ionic strength, or reside within a particular pH range, etc. Tn ESI, salt in the sample can prevent detection by lowering the ionization or by clogging the nozzle. This problem is addressed by presenting the analyte in low salt and/or by the use of a volatile salt. In the case of MALDI, the analyte should be in a
solvent compatible with spotting on the target and with the ionization matrix employed. Tn embodiments, the method further includes identifying the antibody fragments, for example the sequence of the antibody fragments. In embodiments, the method further includes identifying the post-translational modification present on the antibody fragments. In embodiments, the method further includes post-translational modification profiling of the antibody of interest. In embodiments, the method further includes post-translational modification mapping of post- translational modification hotspots by reduced peptide mapping LC-MS/MS analysis.
[00165] Although specific embodiments have been described above in detail, the description is merely for purposes of illustration. It should be appreciated, therefore, that many aspects described above are not intended as required or essential elements unless explicitly stated otherwise. Modifications of, and equivalent components or acts corresponding to, the disclosed aspects of the example embodiments, in addition to those described above, can be made by a person of ordinary skill in the art, having the benefit of the present disclosure, without departing from the spirit and scope of embodiments defined in the following claims, the scope of which is to be accorded the broadest interpretation so as to encompass such modifications and equivalent structures.
[00166] The following examples are provided to illustrate particular features of certain embodiments. However, the particular features described below should not be considered as limitations on the scope of the invention, but rather as examples from which equivalents will be recognized by those of ordinary skill in the art.
EXAMPLES
[00167] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, room temperature is about 25 °C, and pressure is at or near atmospheric.
[00168] Reagents and Materials. Deionized water was generated with a Milli-Q integral 10 water purification system with a MilliPak Express 20 filter (MilliporeSigma, Burlington, MA).
NTSTmAb (Reference material 8671 , humanized IgGljc monoclonal antibody) was purchased from the National Institute of Standards and Technology (Gaithersburg, MD). All other antibodies including mAbl-7 and bsAbl-3 were generated internally by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY). Dimethyl sulfoxide (DMSO, HPLC grade) was purchased from Thermo Fisher Scientific (Rockford, IL). Urea (BioXtra) was purchased from MilliporeSigma. ProteinSimple methyl cellulose (MC) solution at 0.5% and 1%, Pharmalytes (broad range pH 3-10), and pl markers were purchased from VWR International (Radnor, PA). ZipChip HRN chips with a 22 cm separation channel and a native assay kit with Native Antibodies background electrolyte (BGE) were acquired from 908 Devices (Boston, MA).
[00169] Sample preparation. To remove N-glycans from each heavy chain CH2 domain, NISTmAb sample was treated with PNGase F (1 IUB milliunit per 10 pg of protein) at 45 °C in Milli-Q water for 1 hour.
[00170] For bsAb impurity analysis, the concentration of each bsAb stock solution and two homospecific mAb impurities (referred to as HC/HC and HC*/HC*) were measured based on the UV absorbance at 280 nm and the corresponding extinction coefficient. A series of solutions were prepared through mixture of bsAb with percentages of homospecific mAb impurities at 0.2% and 1.0%.
[00171] Forced degradation study. NIST IgGl mAb (5 mg/mL, pH 6.0) was incubated at 45 °C for 0, 1, 4, 8, 15 and 28 days.
[00172] IdeS treatment. For subunit analysis, each NISTmAb sample was diluted to 2 mg/mL with Milli-Q water. Then 125 units of IdeS (Promega) was added to 100 pg of mAb at enzyme/ anti body ratio of 1 .25/1 . The mixture was incubated at 37 °C with shaking at 600 rpm for 30 minutes to generate F(ab’)2 and Fc fragments. Control and stressed samples after each study/treatment were stored immediately at -20 °C. A summary of the method is shown in FIG. 1.
[00173] Native microfluidic CE-MS (nCE-MS). The intact mass analysis of antibodies and charge variants was conducted with the ZipChip CE interface (908 Devices, Boston, MA) coupled to an Exactive Plus EMR Orbitrap mass spectrometer (Thermo Scientific, Bremen, Germany). Samples were loaded on the sample well of a microfluidic chip by a model 840 autosampler with a pressure assistance start time at 0.2 min and a replicate delay of 30 seconds. The injection volume was 1 nL. Charge variants were separated in the separation channel of the
microfluidic chip by using Native Antibodies BGE, 3.8% DMSO, pH ~5.5, under a field strength of 650 V/cm for 15 min. Each separated charge variant species was then ionized and subjected to MS analysis. MS data acquisition was performed through a full scan at a resolution of 17,500 in positive mode with a scan range of 1000-10000 m/z, in-source CID at 100 eV, AGC at 3e6, maximum injection time of 50 ms, and 3 microscans. The ESI parameters were set with spray voltage at 0, capillary temperature at 300 °C, S-lens at 150, sheath gas at 2, auxiliary gas at 0, and trapping gas at 1.
[00174] Strong cation exchange chromatography. Antibody charge variants were separated on a MabPac SCX-10 column (4 x 250 mm) and an Agilent 1290 Infinity HPLC. The pH gradient was optimized according to the tested antibody’s theoretical pl value. Mobile phase A (MPA) and mobile phase B (MPB) were CX-1 pH gradient buffer A and B with pH 5.6 and 10.2 (Thermo Fisher Scientific), respectively. Briefly, for IgG4 and bispecific IgG4 antibodies, the charge variants were separated with a pH gradient from 5% to 15% MPB in 30 min. For IgGl antibodies, the pH gradient was adjusted from 45% to 70% MPB in 30 min. Absorbance was measured at a UV wavelength of 280 nm. The flow rate was set to 0.8 mL/min, and the column temperature was set to 25 °C.
[00175] Imaged capillary isoelectric focusing. The final sample solution contained 0.5 mg/mL protein, 4% (v/v) pH 3-10 Pharmalytes, 2 M urea, and 0.35% (w/v) methylcellulose. Samples were prepared in triplicate in the presence or absence of pl markers. Each sample was hydrodynamically injected into a fluorocarbon-coated silica capillary (100 mm inner diameter, 50 mm observable window, ProteinSimple, San Jose, CA) at 2 bar for 70 seconds with a ProteinSimple iCE3 system. Samples were subsequently pre-focused for 1 minute at 1.5 kV, then subjected to a 7.0 minute focusing period at 3 kV with 100 mM sodium hydroxide as the catholyte and 80 mM phosphoric acid as the anolyte, both in 0.1% (w/v) methyl cellulose. Proteins were monitored during focusing according to the UV absorbance at 280 nm with a scanning charge-coupled device (CCD) camera. Electropherograms were generated with CCD detection of UV light absorption across the separation capillary.
[00176] Data analysis. Raw MS spectra were analyzed in Thermo Xcalibur 4.3.73.11 and deconvoluted with Intact Mass™ software version 3.1 1-1 (Protein Metrics Inc., Cupertino, CA) for charge variant analysis. Base peak chromatograms (BPCs) were processed with Microsoft Excel macros for the same mAb experiment. For data acquired with an Agilent HPLC system,
the data were analyzed in OpenLAB CDS ChemStation Edition Rev. C.01 .07 SR2.
Example 1. Investigation of sensitivity of nCE-MS for therapeutic antibodies
[00177] This disclosure sets forth the development of a high-resolution, high-sensitivity and high-throughput native capillary electrophoresis (CE)-mass spectrometry (MS) method for antibody charge heterogeneity analysis. A panel of fifteen antibodies, including IgGl, IgG4 and bispecific mAbs, were analyzed using the Zipchip nCE-MS method.
[00178] ZipChip nCE-MS combined with nanospray ESI provides ultra-high sensitivity in detecting low abundant charge variant species. The method sensitivity of nCE-MS in analyzing various types of IgG was evaluated by separate injection of different amounts of antibody from 0.01 ng to 1 ng on the chip. The antibody charge separation profile was extracted with BPCs with mass range from 4000 to 9000 m/z, as shown in FIG. 2. In the case of IgGl antibodies for both NISTmAb and mAbl, a limit of detection (LOD) of 0.01 ng was achieved, as shown in FIG. 2A, FIG. 2B, and FIG. 4A. For IgG4, mAb2 and bsAbl, the MS signal was detected down to 0.02 ng and 0.05 ng, respectively, as shown in FIG. 2C, FIG. 2D, and FIG. 4B. At the LOD for all four mAbs including IgGl, lgG4, and bispecific lgG4, the mass spectra of the main species of each antibody showed a high signal-to-noise ratio, thus demonstrating the excellent sensitivity of the nCE-MS method, as shown in FIG. 3. Moreover, the charge variant profile was directly observed at the LOD for all four mAbs. No run-to-run injection carryover was observed for the nCE-MS method, as shown in FIG. 4C.
[00179] The high sensitivity of the nCE-MS method was also demonstrated by the observation of truncation species with low amounts of sample injection. A deglycosylation reaction step removed all N-glycans attached to the mAb, thus decreasing the proteoform complexity and increasing the sensitivity to detect sequence variations. The electropherogram of deglycosylated NISTmAb showed identical charge variant profile and identifications to those of intact NISTmAb, as shown in FIG. 2A and FIG. 5 A. In the A2 acidic variant, Fab glycosylation was detected with a 2 ng injection, as shown in FIG. 5B (Yan et al., 2018). Additionally, three truncation species on the upper hinge region were detected including the cleavage at Cys223/Asp224, Lys225/Thr226, and His227/Thr228, as shown in FIG. 5C and 5D, thus demonstrating the high sensitivity of the nCE-MS method (Yan et al., 2018).
[00180] In order to assess the sensitivity of the method for additional fragmented and truncated species, a forced degradation study and subunit digestion study was conducted using NISTmAb.
The NTSTm Ab reference standard and its heat-stressed forms were analyzed following incubation at 45 °C for up to 28 days. Samples with different incubation times were cleaved by IdeS digestion to generate F(ab’)2 or Fc associated subunit species. The intact mass analysis of both control and stressed antibodies was conducted using a universal Zipchip nCE-MS method. The PTM hotspots were identified by reduced peptide mapping LC-MS/MS analysis to elucidate the elevated charge variants under stressed conditions. Intact mass data was processed by PMi- Intact software. The elevated charge variants were allocated to F(ab’)2 or Fc by the subunit charge variant analysis. Reduced peptide mapping data was processed by BioPharma Finder 3.0 and Skyline-daily 4.2 for PTMs identification and quantification, respectively.
[00181 J Deconvoluted mass data indicated that 4 major Fab cleavages at the upper hinge region of NISTmAb were generated upon 28-day heat stress, in addition to significantly increased acidic variant (Al) compared to the control (FIG. 6 and Table 2).
Note: ND-not detected
[00182] Acidic and basic charge variants were well separated from the main peak for the NIST antibody standard by Zipchip CE running at native conditions. The MS analysis identified two
basic variants corresponding to the antibody with 1 and 2 unprocessed C-terminal lysines on the heavy chain, while an acidic variant was mainly caused by deamidation.
[00183] F(ab’)2 and Fc were well separated by the universal nCE-MS method. All minor peaks were identified, as shown in FIGs. 7A-7C. New charge variants resulting from 28-day incubation are indicated in blue shaded regions. Two basic variants with 1 and 2 unprocessed C- terminal lysines were located in the Fc region (FIG. 7C). The basic variant 3, resulting from Fab cleavage at His227/Thr228 in stressed sample (45 °C, D28), was identified as F(ab’)2 basic variant (b* 1) in FIG. 7B. All other Fab cleavage sites were found in the acid region of F(ab’)2 and in the same order as those were identified during intact antibody analysis. For Fc acidic region, a new acidic variant Ala caused by Asp isomerization showed up in D28 sample. Compared to main Fc, the +1 Da mass increase of both Al and Ala indicated that the acidic variant might be caused by deamidation. This was confirmed by peptide mapping, as shown in Table 3.
Example 2. Separation of antibody mixtures for high-throughput intact mass analysis
[00184] Three IgGl mAbs in mixture 1 (FIG. 8A) and five IgG4 bispecific mAbs in mixture 2 (FIG. 8B) were well separated by the ZipChip nCE-MS method of the present invention, which can be applied for intact mass analysis of co-formulated drugs. Even if two antibodies comigrated together (blue shaded area in FIG. 8C), those can be identified individually from native
MS data, as shown in FIG. 8D and FIG. 8E. FIG. 8E shows the convoluted spectra. Besides high-resolution charge variant analysis of a single antibody, the ZipChip nCE-MS method can also be used as a high-throughput and high-sensitivity approach for intact mass analysis of antibody mixture and ADCs.
Example 3. System Robustness
[00185] System robustness is important to assess when method is applied in various analytical tasks in industrial settings. This property is particularly crucial for comparability studies such as cell line selection and process optimization. As shown in FIG. 9 for an IgG4 mAb3, three lots from process 1 and two lots from process 2 were subjected to nCE-MS analysis. The charge variant profdes from the nCE-MS analysis of the five samples were highly comparable, showing three basic variants and three acidic variants. Moreover, MS analysis allowed for PTM characterization and the identification of processes related PTM differences, as shown in Table 4.
[00186] In the main species, more non-glycosylated species were observed in samples from process 2 than process 1, as shown in FIG. 10A. Additionally, higher levels of glycine loss with
amidation were observed in samples from process 1 than process 2, as shown in basic variant 1 , as shown in FIG. 10B. The highly comparable charge variant profde, in addition to the consistent results among samples from the same process, demonstrated the system robustness of nCE-MS analysis, which is suitable for comparability studies.
Example 4. Comparison of antibody charge variant separation among nCE-MS, SCX-UV, and iCIEF
[00187] nCE-MS is a new method for charge variant analysis, in contrast to SCX and iCIEF, which are commonly used as characterization and release assays. In this study, the nCE-MS method was first compared to SCX with UV detection. Three types of antibodies including IgGl NISTmAb, IgG4 mAb2, and bispecific IgG4 bsAb2 were used for this comparison. The charge variant separation profiles of these three types of antibodies are shown in FIG. 11 between the SCX-UV method using a pH gradient and nCE-MS. Comparable high-resolution charge variant separations of all types of IgG were obtained between platforms, including the same number of basic and acidic variants. Compared with SCX-UV, which usually requires injection of more than 10 pg, the nCE-MS method enabled high resolution charge variant separation with only a 1 ng injection. More importantly, each charge variant was directly identified by online MS analysis. In comparison, the SCX-UV method generally uses MS-incompatible salts, and often requires either fraction collection or two-dimensional liquid chromatography coupled with MS to elucidate the PTMs in the charge variants (Alvarez et al. 2011, Anal. Biochem. 419(1): 17-25; Jaag et al, 2021, J. Chromatogr. A, 1636:461786).
[00188] Recently, SCX coupled to native MS (SCX-nMS) has been used for charge variant analysis of mAbs (Yan et al., 2018; Ma etal.,' Haberger etal., 2021, J. Am. Soc. Mass Spectrom. , 32(8):2062-2071). Similar charge variant profiles have been obtained between SCX-nMS and nCE-MS analysis (Fussl et al., 2Q2Q, Anal. Chem., 92(7):5421-5438). However, sample amounts of approximately 50 pg are often required for SCX-nMS with post-column flow splitting to enhance sensitivity, and to provide the same detection of truncated species and Fab glycosylation species shown in FIG. 5 (Yan et al., 2018; Ma et al.). In comparison, only a 2 ng injection (with 10 pg transferred to the sample well) was required with the integrated nCE-MS method. Additionally, the unused portion of the protein sample could be recovered from the ZipChip interface after the nCE-MS experiment and subjected to other assays, thus providing experimental flexibility, particularly in the drug discovery stage and other situations in which
protein amounts are limited
[00189] Charge variant separation between iCIEF and nCE-MS was also compared. Three types of antibodies including IgGl mAb4, IgG4 mAb5, and bispecific IgG4 bsAb3 were used to compare these two methods. As shown in FIG. 12, the charge variants between the iCIEF and nCE-MS analysis showed several differences. In the case of IgGl mAb4, the number of acidic variants between these two methods differed and the nCE-MS methods showed fewer acidic species than the iCIEF method, as shown in FIG. 12A. In contrast, the basic variant was more clearly observed in the nCE-MS method than the iCIEF method. In the case of both IgG4 mAb5 and bispecific IgG4 bsAb3, comparable electropherograms were observed between these two methods, as shown in FIG. 12B and 12C. A recent study has suggested that electropherograms between iCIEF and nCE-MS analysis are comparable (Cao et al. . In the examples provided in this study, differences in electropherograms were observed, such as for IgGl mAb4. The nCE- MS method also showed relatively lower resolution separation in the acidic region than iCIEF analysis, possibly because of tailing from the main species and potential diffusion caused by peak broadening during the long migration time in the separation channel. The differences are likely due to the different nature for separation between these two methods, where iCIEF separates analytes according to intrinsic pl whereas nCE-MS method is based on capillary zone electrophoresis that takes into account both the solvated charge and size of the analytes.
Recently, direct coupling of iCIEF and MS has been used to accelerate peak identification for iCIEF analysis, however, the method remains under development, and wide adoption of this technique has yet to occur (Mack et al. ; He et al. ; Dai et al. , 2018, Anal. Chem. , 90(3):2246- 2254). According to the observations in this study, nCE-MS is a highly sensitive, high- resolution approach for the characterization of antibody charge variants, and the similarity in electropherograms between iCIEF and nCE-MS may aid in the identification of antibody charge variants for iCIEF assays.
[00190] Despite the advantages of nCE-MS analysis, iCIEF and SCX assays are performed with UV detection, which can directly enable quantification of charge variants, whereas nCE-MS relies on BPCs from MS and provides the relative quantification. Additionally, the relative quantification is also impacted by the differential ionization efficiency among acidic, main, and basic species. The SCX-nMS method with flow splitting to a UV detector can be used to quantitatively measure the percentages of charge variants (Yan et al., 2018).
Example 5. Bispecific antibody impurity analysis
[00191] Impurities in bsAb therapeutics are a subject of interest for the pharmaceutical industry (Yan et al., 2019, Anal. Chem., 91(17): 11417-11424). In this study, the bsAb of interest comprised two identical light chains and two different heavy chains, HC and HC* (Smith et al., 2015, Sci. Rep., 5(1): 17943; Tustian et al., 2016, MAbs, 8(4): 828-838). Although homospecific mAb impurities, which are composed of two identical light chains and two identical heavy chains (either HC or HC*), are removed during purification in the manufacturing process, some residual homospecific mAb impurities (referred to as HC/HC and HC*/HC*) remain in the desired bsAb product (Li, 2019, Protein Expr. Purif., 155(112-119). Quantification of these homospecific mAb species is necessary to ensure product safety and efficacy. The nCE-MS method was used for the analysis of the bispecific IgG4 bsAbl, as shown in FIG. 13A. For this bispecific antibody, common charge variants were detected, including antibody with one or two unprocessed C-terminal lysine residues in the basic variants, and deamidation, glycation, as well as one or two N-acetylneuraminic acid residues in the acidic variants, as shown in Table 5.
[00192] Interestingly, in the zoom-in view, low abundant HC/HC and half antibodies were
observed after 20 ng injection into the nCE-MS, thus demonstrating the high sensitivity of the nCE-MS method, as shown in FIG. 13B and FIG. 14. However, HC*/HC* was not detected in the sample. To understand the relative abundance of HC*/HC* impurity in the bsAbl, bsAbl sample was spiked with HC*/HC* impurity at a ratio of 1 :500 (0.2%) and 1 : 100 (1%) and then analyzed using nCE-MS. Because the pl values of the HC and HC* are different, HC/HC and HC*/HC* impurities and bsAb should be separated in the nCE-MS method. In this spiking experiment, the HC*/HC* impurity was detected at a level of 0.2% in spiked bsAbl samples, as shown in FIG. 13C and FIG. 15. The high sensitivity of the nCE-MS method was also demonstrated by the observation of separate peaks for charge variants of HC*/HC* impurity at a level of 1%, as shown in FIG. 13D. With this method, the HC*/HC* impurity was determined to be below 0.2%, if any, in the bsAbl sample.
Example 6. Charge heterogeneity analysis of new formats of biotherapeutics
[00193] In addition to traditional formats of mAbs, including IgGl, IgG4, and bispecific antibodies described in the preceding sections, nCE-MS can analyze the charge variants of new formats of antibody derivatives. For example, mAb6 is a therapeutic antibody in “N-l” format where one Fab arm is removed, and it has Gin in the N-terminus of the HC. During mAb manufacturing, Gin would be converted into pyroglutamate. However, a small percentage of Gin is often found to be unconverted, thus resulting in a basic charge variant relative to the main species, which is a mAb with complete conversion of Gin to pyroglutamate (Liu et al., 2019, J. Pharm. Sci., 108(10): 3194-3200). nCE-MS analysis revealed eight species, including four basic variants and three acidic variants, as shown in FIG. 16A and Table 6.
[00194] In the basic variants, PTMs including one or two unprocessed C-terminal Lys residues, one unconverted Gin, and a combination of one unprocessed C-terminal Lys residue and one unconverted Gin were observed. Three acidic variants included PTMs such as deamidation, glycation, and one to three N-acetylneuraminic acid residues.
[00195] For mAb7, an additional Fab arm was connected to the normal mAb with G4S linkers, and it is referred as “N+l” format. nCE-MS analysis revealed five species, including two basic variants and two acidic variants, as shown in FIG. 16B and Table 7.
[00196] The basic variants were attributed mainly to one or two unprocessed C-terminal Lys residues and N-terminal pyroglutamate formation. In the acidic variants, in addition to commonly observed PTMs such as deamidation and glycation, mass differences matching O- glycosylation were also detected, as shown in FIG. 17. The O-glycan has a structure of Xyl+Gal+Gal+GlcA, which is a common O-glycan in mAb formats using G4S linkers, as reported in previous publications (Haberger et al. Spahr et al., 2014, MAbs, 6(4):904-914; Spencer et al, 2013, J. Pharm. Sci, 102(11):3920-3924). The presence of O-glycan was
confirmed by reduced peptide mapping. Tn summary, nCE-MS is suitable for the analysis of new formats and can reveal PTMs unique to common mAbs such as O-glycosylation.
[00197] In this study, characterization of charge variants and impurities of therapeutic antibodies was demonstrated with nCE-MS method, which provides high resolution separation and high sensitivity detection, with excellent system robustness. The electropherograms provided by nCE-MS analysis were similar to the chromatograms from SCX and the electropherograms from iCIEF. Therefore, this method can be used for peak identification in SCX and iCIEF studies. Antibodies with close pl values can be separated well. Co-migrated antibodies were identified individually based on simplified native mass spectra. Increased levels of acidic variants and Fab fragments resulting from incubation under stressed conditions were localized within the F(ab’)2 and Fc domains by subunit analysis. Furthermore, higher resolution subunit analysis revealed an additional acid variant introduced from isomerization and increased half glycosylated species under stressed condition. Moreover, high sensitivity detection enables the detection of impurities including truncations in NISTmAb and homospecific mAb impurities in bsAb. In addition to common therapeutic antibodies, nCE-MS analysis can be applied to characterize new modalities including mAbs with or without Fab arms and to detect PTMs such as O-glycosylation. Thus, the nCE-MS analysis shows great potential in the development of biopharmaceuticals, and implementation of this analysis may accelerate the timeline for elucidating drug candidate quality attributes and assist in investigations in product manufacturing.
[00198] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Claims
1. A method for characterizing a monospecific antibody in a mixture of a bispecific antibody and its monospecific antibody side products, comprising:
(a) separating a mixture of a bispecific antibody and its monospecific antibody side products by molecular weight and/or charge in one or more capillaries using capillary electrophoresis;
(b) eluting said separated antibody and antibody side products from said one or more capillaries; and
(c) determining the mass of said eluted antibody and antibody side products by mass spectrometry, thereby characterizing said monospecific antibody, wherein said monospecific antibody is maintained in native conditions, and wherein said capillary electrophoresis is in an integrated microfluidic platform.
2. The method of claim 1, further comprising determining a relative or absolute amount of said monospecific antibody in said mixture.
3. The method of claim 1, wherein said mixture includes an internal standard.
4. The method of claim 1 , wherein said one or more capillaries comprise a separation matrix.
5. The method of claim 4, wherein said separation matrix comprises a sieving matrix configured to separate proteins by molecular weight.
6. The method of claim 1, wherein said monospecific antibody is of isotype IgGl, IgG2, IgG3, IgG4, or mixed isotype.
7. The method of claim 1, further comprising characterizing a second monospecific antibody in said mixture.
8. The method of claim 1, wherein an injection volume in said one or more capillaries is between about 1 nL and about 10 nL.
9. The method of claim 8, wherein an injection volume in said one or more capillaries is about 1 nL.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/870,368 | 2022-07-21 | ||
US17/870,368 US20230043610A1 (en) | 2019-01-31 | 2022-07-21 | Native microfluidic ce-ms analysis of antibody charge heterogeneity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024020199A1 true WO2024020199A1 (en) | 2024-01-25 |
Family
ID=87747958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/028357 WO2024020199A1 (en) | 2022-07-21 | 2023-07-21 | Native microfluidic ce-ms analysis of antibody charge heterogeneity |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024020199A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100331527A1 (en) | 2009-06-26 | 2010-12-30 | Regeneron Pharmaceuticals, Inc. | Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format |
US20200249241A1 (en) * | 2019-01-31 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Native Microfluidic CE-MS Analysis of Antibody Charge Heterogeneity |
-
2023
- 2023-07-21 WO PCT/US2023/028357 patent/WO2024020199A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100331527A1 (en) | 2009-06-26 | 2010-12-30 | Regeneron Pharmaceuticals, Inc. | Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format |
US20200249241A1 (en) * | 2019-01-31 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Native Microfluidic CE-MS Analysis of Antibody Charge Heterogeneity |
Non-Patent Citations (61)
Title |
---|
ALESSANDRI ET AL., MABS, vol. 4, 2012, pages 509 - 20 |
ALVAREZ ET AL., ANAL. BIOCHEM., vol. 419, no. 1, 2011, pages 17 - 25 |
CAI ET AL., BIOTECHNOLOGY AND BIOENGINEERING, vol. 108, 2011, pages 404 - 12 |
CAO, J. PHARM. BIOMED. ANAL., vol. 204, 2021, pages 114251 |
CAOSUN ET AL., ANAL. BIOCHEM., vol. 625, 2021, pages 114214 |
CARILLO SARA ET AL: "In-depth analysis of monoclonal antibodies using microfluidic capillary electrophoresis and native mass spectrometry", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 185, 1 June 2020 (2020-06-01), AMSTERDAM, NL, pages 113218, XP093093181, ISSN: 0731-7085, DOI: 10.1016/j.jpba.2020.113218 * |
CHAN ET AL., NAT. REV. IMMUNOL., vol. 10, no. 50, 2010, pages 301 - 316 |
CHIU ET AL., ANTIBODIES, vol. 8, 2019, pages 55 |
CUESTA-MATEOS ET AL., FRONT. IMMUNOL., vol. 8, 2017, pages 1936 |
DEV. COMP. IMMUNOL., vol. 55-77, 2003 |
DEYANOVA ET AL., ELECTROPHORESIS, vol. 42, no. 4, 2021, pages 460 - 464 |
DU ET AL., MABS, vol. 4, no. 5, 2012, pages 578 - 585 |
ERIN A. REDMAN ET AL: "Integrated Microfluidic Capillary Electrophoresis-Electrospray Ionization Devices with Online MS Detection for the Separation and Characterization of Intact Monoclonal Antibody Variants", ANALYTICAL CHEMISTRY, vol. 87, no. 4, 17 February 2015 (2015-02-17), US, pages 2264 - 2272, XP055326957, ISSN: 0003-2700, DOI: 10.1021/ac503964j * |
FEKETE ET AL., J. PHARM. BIOMED. ANAL., vol. 113, 2015, pages 43 - 55 |
FUSSL ET AL., ANAL. CHEM., vol. 90, no. 3, 2018, pages 2246 - 2254 |
FÜSSL FLORIAN ET AL: "Comparative Elucidation of Cetuximab Heterogeneity on the Intact Protein Level by Cation Exchange Chromatography and Capillary Electrophoresis Coupled to Mass Spectrometry", ANALYTICAL CHEMISTRY, vol. 92, no. 7, 27 February 2020 (2020-02-27), US, pages 5431 - 5438, XP093092917, ISSN: 0003-2700, DOI: 10.1021/acs.analchem.0c00185 * |
GENOME TECHNOLOGY, pages 52 |
GOETZE ET AL., GLYCOBIOLOGY, vol. 21, 2011, pages 949 - 59 |
GOETZE ET AL., GLYCOBIOLOGY, vol. 22, 2012, pages 221 - 34 |
GSTÖTTNER CHRISTOPH ET AL: "Intact and subunit-specific analysis of bispecific antibodies by sheathless CE-MS", ANALYTICA CHIMICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1134, 21 August 2020 (2020-08-21), pages 18 - 27, XP086291793, ISSN: 0003-2670, [retrieved on 20200821], DOI: 10.1016/J.ACA.2020.07.069 * |
GSTÖTTNER CHRISTOPH ET AL: "Sheathless CE-MS as a tool for monitoring exchange efficiency and stability of bispecific antibodies", ELECTROPHORESIS, vol. 42, no. 1-2, 21 September 2020 (2020-09-21), Hoboken, USA, pages 171 - 176, XP093093266, ISSN: 0173-0835, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/elps.202000166> DOI: 10.1002/elps.202000166 * |
HE ET AL., ELECTROPHORESIS, 2022 |
HUANG ET AL., ANALYTICAL CHEMISTRY, vol. 77, 2005, pages 1432 - 9 |
JIN ET AL., MABS, vol. 11, no. 1, 2019, pages 106 - 115 |
KHATRI ET AL., ANAL. CHEM., vol. 89, no. 12, 2017, pages 13013 - 13020 |
KHATRIDYKSTRA ET AL., J. AM. SOC. MASS SPECTROM., vol. 32, no. 8, 2021, pages 2062 - 2071 |
LABRIJN ET AL., NAT. REV. DRUG DISCOV., vol. 18, no. 8, 2019, pages 585 - 608 |
LEFRANC ET AL., IMGT UNIQUE NUMBERING FOR IMMUNOGLOBULIN AND T CELL RECEPTOR VARIABLE DOMAINS AND IG SUPERFAMILY V-LIKE DOMAINS, vol. 27, no. 1 |
LI Y ET AL., MABS, 2016 |
LIU ET AL., J. PHARM. SCI., vol. 108, no. 10, 2019, pages 3194 - 3200 |
LIU ET AL., J. PHARM. SCI., vol. 97, no. 7, 2008, pages 2426 - 2447 |
LIU ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, 2008, pages 29266 - 72 |
LIU ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, 2011, pages 11211 - 7 |
M. POTTER, STRUCTURAL CORRELATES OF IMMUNOGLOBULIN DIVE SITY, vol. 2, no. 1 |
MA ET AL., MABS, vol. 12, no. 1, 2020, pages 1763762 |
MACK ET AL., ELECTROPHORESIS, vol. 40, no. 23-24, 2019, pages 3084 - 3091 |
OUELLETTE ET AL., MABS, vol. 5, 2013, pages 432 - 44 |
REDMAN ET AL., ANAL. CHEM., vol. 87, no. 4, 2015, pages 2264 - 2272 |
REDMAN ET AL., ANAL. CHEM., vol. 88, no. 4, 2016, pages 2220 - 2226 |
RIBEIRO DA SILVA ET AL., J. CHROMATOGR. A, vol. 1636, 2021, pages 461786 |
RODRIGUES ET AL., PROG. RETIN. EYE RES., vol. 28, no. 2, 2009, pages 117 - 144 |
RODRIGUESLU ET AL., J. BIOMED. SCI., vol. 27, no. 1, 2020, pages 1 |
ROGSTAD ET AL., J. AM. SOC. MASS SPECTROM., vol. 28, no. 5, 2017, pages 786 - 794 |
RUNCIE ET AL., MOL. MED, vol. 24, no. 1, 2018, pages 50 |
SALAS-SOLANO ET AL., CHROMATOGRAPHIA, vol. 73, no. 11, 2011, pages 1137 - 1144 |
SCOTT ET AL., NAT. REV. CANCER., vol. 12, no. 4, 2012, pages 278 - 287 |
SEUNG ET AL., NATURE, vol. 603, no. 7900, 2022, pages 328 - 334 |
SMITH ET AL., SCI. REP., vol. 5, no. 1, 2015, pages 17943 |
SPAHR ET AL., MABS, vol. 6, no. 4, 2014, pages 904 - 914 |
SPARROW ET AL., BULL. WORLD HEALTH ORGAN., vol. 95, no. 3, 2017, pages 235 - 237 |
SPENCER ET AL., J. PHARM. SCI, vol. 102, no. 11, 2013, pages 3920 - 3924 |
SPIESS ET AL., MOL. IMMUNOL., vol. 67, no. 95-106, 2015 |
SURV. IMMUNOL. RES., vol. 27-42, 1983 |
TAMBUYZER ET AL., NAT. REV. DRUG DISCOV., vol. 19, no. 2, 2020, pages 93 - 111 |
TUSTIAN ET AL., MABS, vol. 8, no. 4, 2016, pages 828 - 838 |
WARD ET AL., NATURE, vol. 241, 1989, pages 544 - 546 |
WU ZHIJIE ET AL: "High-sensitivity and high-resolution therapeutic antibody charge variant and impurity characterization by microfluidic native capillary electrophoresis-mass spectrometry", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 223, 1 January 2023 (2023-01-01), AMSTERDAM, NL, pages 115147, XP093092913, ISSN: 0731-7085, DOI: 10.1016/j.jpba.2022.115147 * |
WURM, NAT. BIOTECHNOL., vol. 22, no. 11, 2004, pages 1393 - 1398 |
YAN ET AL., ANAL. CHEM., vol. 91, no. 17, 2019, pages 11417 - 11424 |
YIN ET AL., PHARMACEUTICAL RESEARCH, vol. 30, 2013, pages 167 - 78 |
ZHANG ET AL., EEBS LETT, vol. 588, no. 2, 2014, pages 308 - 317 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200249241A1 (en) | Native Microfluidic CE-MS Analysis of Antibody Charge Heterogeneity | |
US20240174737A1 (en) | Online chromatography and electrospray ionization mass spectrometer | |
KR20210120010A (en) | Protein A Chromatography - Electrospray Ionization Mass Spectrometer | |
JP2023116475A (en) | System and method of analysis of protein using liquid chromatography-mass spectrometry | |
JP2022517338A (en) | Methods and systems for identifying and quantifying antibody fragmentation | |
KR20220123116A (en) | Use of Amino Acids to Enhance Signals in Mass Spectrum Analysis | |
US20230266335A1 (en) | Maximizing hydrophobic peptide recovery using a mass spectrometry compatible surfactant | |
JP2020101538A5 (en) | ||
US20230043610A1 (en) | Native microfluidic ce-ms analysis of antibody charge heterogeneity | |
US20240053359A1 (en) | Native microfluidic ce-ms analysis of antibody charge heterogeneity | |
WO2024020199A1 (en) | Native microfluidic ce-ms analysis of antibody charge heterogeneity | |
US11525833B2 (en) | Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis | |
US20230018713A1 (en) | Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms) | |
US20230092532A1 (en) | Method to prevent sample preparation-induced disulfide scrambling in non-reduced peptide mapping | |
CN118076890A (en) | Characterization of proteins by anion exchange chromatography mass spectrometry (AEX-MS) | |
JP2024503996A (en) | Method for identifying scrambled disulfides in biomolecules | |
KR20240053005A (en) | nMass analysis-based strategy for characterizing high molecular weight species of biological products | |
KR20240027090A (en) | Coupling mass spectrometry analysis and isoelectric electrophoresis-based fractionation | |
EA044417B1 (en) | QUANTITATIVE DETERMINATION AND IDENTIFICATION OF DIMERS IN COMPOSITE COMPOSITIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23757733 Country of ref document: EP Kind code of ref document: A1 |